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Abstract 
The efficiency in which HIV-1 can infect, spread and evade the attack of therapeutic 
agents can be attributed to a high mutation rate and frequent recombination events. 
These factors have collectively contributed to the diversity observed in HIV-1 and 
resulted in a multitude of subtypes, sub-subtypes, circulating recombinant forms 
(CRF’s) and unique recombinant forms (URF’s). The aim of this study was to 
investigate HIV-1 diversity in Cape Town using a small cohort of treatment naive 
patients being investigated for HIV Associated Neurocognitive Disorders (HAND). 
Four different genomic domains: gag, pol, accessory and gp41 genes were 
sequenced to subtype the virus. HIV-1 tat was further investigated because the 
dicysteine motif has been reported to play a role in HAND. Viral RNA and proviral 
DNA was extracted from 64 patients and used for the amplification and sequencing 
of the genes. Rega and jpHMM online tools were used to identify HIV-1 subtypes 
and recombinants while Neighbor-joining phylogenetic trees were constructed for 
phylogenetic analysis. The pol gene was further investigated using SCUEAL to 
detect possible intra-subtype recombination and was also screened for the presence 
of transmitted drug resistance. In addition tat sequence datasets retrieved from the 
Los Alamos sequence database were investigated and compared with the newly 
generated sequences for the detection of point mutations and amino acid signature 
patterns. 
Sequencing identified most of the samples as subtype C; however six inter-subtype 
recombinants (AE, A1G, A1CU and two BC) and 9 intra-subtype C recombinants 
were identified. In addition 13% of pol sequences were identified with resistance 
mutations. Signature pattern analysis identified a high level of variability in the tat 
sequences: 68% were identified with C30S31; 29% with the C30C31 mutation and a 
single sequence with a novel mutation C30A31. Functional analysis of these 
mutations indicated that all mutations investigated were capable of inducing 
apoptosis in cell culture. The C30C31 mutation generated the highest level of 
apoptosis, closely followed by the C30A31 mutation. However no statistical 
significance could be detected between tat mutations and the observed levels of 
apoptosis. 
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INTRODUCTION 
In 2011, it was estimated that 23.5 million people were living with HIV-1 in sub-
Saharan Africa with an adult prevalence of between 15-49% (UNAIDS, 2012). 
Although the HIV epidemic has reached a plateau in South Africa, the country still 
has the highest prevalence of HIV infected individuals. However, an increase in 
prevalence has been reported in individuals aged 25 years and above as a result of 
the availability of ARV treatment and elevated levels of promiscuity. The prevalence 
of HIV in the different provinces of South Africa is variable, with the highest 
prevalence of 39.5% (2009-2010), among 15-49 year olds, recorded in KwaZulu-
Natal. Other provinces with high prevalence levels include Mpumalanga (35.1%), 
Free State (30.6%) and Gauteng (30.4%). A significant increase in prevalence of 
16.9% to 18.5% was also observed in the Western Cape in 2010. A recent antenatal 
survey also indicated that most of these HIV-1 infections occurred in young women 
aged between 30-34 years (Global AIDS Progress Report, 2012). Excessive genetic 
variability is a main feature of HIV-1 epidemiology and has resulted in 9 subtypes, 2 
sub-subtypes, at least 55 circulating recombinant forms (CRFs) and numerous 
unique recombinant forms (URFs) being identified (http://www.hiv.lanl.gov ).  
Epidemiological studies have identified subtype C as the most prevalent form of HIV-
1 in the world (Ariën et al., 2007). Subtype C dominates in regions of sub-Saharan 
Africa, India, Brazil and China and is responsible for almost 50% of all global HIV-1 
infections. Subtype B circulates in the Americas, Western Europe and Australia while 
subtype A is the main HIV-1 circulating form in Eastern Africa (Kenya, Uganda, and 
Tanzania) and Eastern Europe. Due to recombination and high mutation rates in the 
life cycle of HIV-1, viral subtypes can differ by as much as 20-25% and therefore 
have varying degrees of pathogenicity, disease progression, co-receptor usage and 
transmissibility (Ataher et al., 2012).  
The aim of this study was to subtype and characterize HIV-1 in a cohort of patients 
being investigated for HAND. In the literature review, I will briefly discuss the 
characteristics of HIV-1, the diversity of the virus and focus on the structure and 
function of the HIV-1 tat gene and Tat protein. HIV-1 and neurocognitive disorders 
will also be briefly reviewed. Finally, the aim and objectives of the study will be 
stated.  
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LITERATURE REVIEW 
1.1. Human Immunodeficiency Virus type-1 
1.1.1 The history and epidemiology of HIV-1 
AIDS was first discovered in the 1980s when five men presented with Pneumocystis 
carinii pneumonia (PCP), a rare opportunistic infection that affected individuals with 
compromised immune systems (Follansbee et al., 1982). These men died within 
months and soon more men presented with a rare skin cancer called Kaposi 
sarcoma (Gottlieb et al., 1981). In both instances, the underlying cause for the 
infection was unknown. However these infections were not isolated and more cases 
arose which prompted the monitoring of the outbreak. Similar cases were also 
reported in Africa, but manifested in both homosexual and heterosexual populations 
(Piot et al., 1984). A disease pattern was soon identified and was characterized by a 
low CD4+ cell count, lymphadenopathy and infection by opportunistic infections 
(Basavapathruni & Anderson, 2007).  
In 1983 Montagniers’ group isolated a virus named "lymphadenopathy-associated 
virus," or LAV from a patient with persistent lymphadenopathy (Barré-Sinoussi et al., 
1983). The virus appeared to be related to the Lentivirus genus of the Retroviridae 
family and was named Human Immunodeficiency Virus (HIV) (Levy et al., 1984; 
Basavapathruni & Anderson, 2007). HIV-1 has since spread across the world, but in 
an irregular distribution of subtypes resulting in HIV-1 hotspots like sub-Saharan 
Africa. The global spread of HIV-1 and the areas dominated by specific subtypes are 
indicated in Figure 1.1.  
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Figure 1.1. Circulation of HIV-1 subtypes and recombinant forms in the world. This geographical 
distribution highlights the prevalence of subtype C in southern Africa and Subtype B in economically 
developed regions such as North America, Australia and Europe. (Source: 
http://www.pbs.org/wgbh/pages/frontline/aids/art/clademap.gif  
 
1.1.2 HIV-1 viral structure and gene organization  
HIV-1 belongs to the Retroviridae family and Lentivirus genus and is approximately 
100nm in diameter. Its genome consists of two copies of positive stranded viral RNA 
encased in a capsid which is surrounded by a lipid bilayer envelope (env) with 
surface glycoprotein spikes (Figure 1.2). The glycoproteins spikes are derived from 
the env gp160 precursor and composed of the outer surface protein (gp120) and the 
transmembrane protein (gp41), which anchors the spike to the lipid bilayer (Briggs et 
al., 2003; Levy, 2007).  
The matrix protein (p17) lines the inner surface of the HIV-1 virion and encases the 
icosahedral shell of the p24 capsid protein (CA). and the viral enzymes protease 
(PR), integrase (IN), and reverse transcriptase (RT) (Nisole & Saïb, 2004). Pol is 
responsible for the encoding of these enzymes protease, reverse transcriptase, 
RNase H and integrase. Reverse transcriptase is necessary for the transcription of 
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viral RNA into cDNA while integrase is responsible for the integration of the viral 
DNA into the host genome (Levy, 2007; Dicker et al., 2007). The remaining 
regulatory and accessory genes control viral replication and HIV’s ability to infect 
cells (Chan et al., 1997).  
 
                 
Figure 1.2 Graphical presentation of the HIV-1 virion structure. The diagram shows the lipid bilayer 
containing the surface glycoprotein spikes (gp120 and gp41), the matrix protein (p17) which lines the 
inner surface of the HIV-1 virion and the two copies of RNA. Reverse transcriptase integrase and 
protease enzymes can be observed within the p24 capsid, and are necessary for the reverse 
transcription of viral RNA, integration of proviral DNA into the host genome and the cleaving of mature 
polyproteins (Source: http://en.wikipedia.org/wiki/File:HIV_Virion-en.png  and 
http://web.archive.org/web/20041119131214/http://www.niaid.nih.gov/factsheets/graphics/howhiv.jpg ) 
 
The HIV-1 genome is approximately 9.2kb long and composed of structural 
landmarks (LTR, tar, rre, pe, slip, crs and INS), structural genes (gag, pol and env), 
regulatory genes (tat and rev) and accessory genes (nef, vif, vpr and vpu) as 
indicated in Figure 1.3 (HIV sequence compendium, 2011). The long terminal 
repeats (LTRs) flank the genome of the integrated provirus and regulate the 
production of new virus particles with the aid of either HIV-1 or the host cell proteins. 
The U3 region of the LTR contains elements which recruit transcription factors and 
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initiates transcription of viral RNA. U3 transcription activity is low but can be 
enhanced through regulatory proteins such as Tat (Suzuki & Suzuki 2005). The 
structural genes gag, pol and env codes for proteins essential for viral structure. The 
Rev responsive element (RRE) encoded within the env gene facilitates protein 
binding. The SLIP (TTTTTT) element is necessary to generate functional pol. The 
gag gene is a necessary structural component of the virus and generates the viral 
capsid (p24), the nucleocapsid (p6 and p7) and the matrix (p17) (HIV Sequence 
Compendium 2011). 
 
              
 
Figure 1.3: Genome organization of HIV-1. Viral RNA is transcribed into DNA comprised of LTRs 
flanked on either ends of the genome. Structural genes (gag, pol and env) regulatory genes (tat and 
rev) and accessory genes (nef, vif, vpr and vpu) are indicated as well as the proteins encoded by 
each genomic region (Source: Suzuki & Suzuki, 2005), Reprinted with permission from Prof Yuichi 
Suzuki. 
 
The RNA response element TAR is a 59 base stem loop structure localized within 
the first 80 nucleotides of the LTR. Deletion studies have shown that nucleotides 19 
to 42 are sufficient for Tat binding. The TAR RNA contains a 6- nucleotide loop and a 
three-nucleotide pyrimidine bulge which separates helical stems and plays a critical 
role in HIV replication by providing a binding site for the recruitment of the viral 
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transactivator protein Tat (Lalonde et al., 2011). In addition, it has been proposed 
that TAR plays other roles in replication such as: dimerization, strand transfer during 
reverse transcription, a possible HIV-1-derived microRNA (miRNA) during latency, 
and viral packaging (Lu et al., 2011). Mutational studies from Das et al., (1998) 
concluded that the disruption of TAR resulted in reduced levels of genome 
packaging and this was supported by similar results (Clever & Parslow, 1997). A 
summary of HIV-1 protein functions is listed in Table 1.1.  
 
Table 1.1 HIV-1 proteins and their function (Source: Frankel & Young, 1998). 
Protein Function Abbreviation 
Gag 
Capsid structural protein CA 
Matrix protein, myristoylated MA 
Nucleocapsid protein, helps in reverse 
transcription 
NC 
Role in viral budding (L domain) - 
Polymerase 
Reverse Transcription (RT): RNase H-inside 
core 
RT 
Protease Gag/Pol cleavage and maturation PR 
Integrase Viral cDNA integration IN 
Env 
Envelope surface protein SU 
Envelope transmembrane protein TM 
Tat Transactivation Tat 
Rev Regulation of viral mRNA expression Rev 
Nef 
Pleiotropic, can increase or decrease virus 
replication 
Nef 
Vif Promotes virion maturation and infectivity Vif 
Vpr Helps in virus replication, transactivation Vpr 
Vpu 
Helps in virus release, disrupts gp160:CD4 
complex 
Vpu 
Vpx Helps in entry and infectivity (HIV-2 and SIV) Vpx 
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1.1.3 The life cycle of HIV-1   
The life cycle of HIV-1 has two distinct stages, the early phase and the late phase. 
The early phase entails cell binding and integration of the transcribed viral DNA into 
the cell genome, while the late phase begins with the expression of viral genes and 
ends with the release of mature progeny virions (D’Souza & Summers, 2005). The 
initial step of the early phase is the binding and adsorption of viral particles to the cell 
surface proteins of the viral lipid bilayer. Interactions between viral envelope 
glycoproteins and CD4+ receptors on host T-cells facilitate viral entry into the host 
cell. This interaction leads to conformational changes in the CD4+ T cell receptor and 
gp120 glycoproteins. In addition to this, the recruitment of the chemokine co-
receptors CXCR4 and CCR5 is initiated. A second interaction between CXCR4 or 
CCR5 and gp120 results in a second conformational change. These conformational 
changes culminate in the dissociation of gp120 from gp41, and the alteration of gp41 
to its fusogenic conformation. Entry of virions into host cells is finally achieved by the 
insertion of gp41 fusion peptide into the target membrane as illustrated by Figure 
1.4.  
Fusion of viral and cellular membranes releases the viral genome into the cytoplasm. 
The viral core is uncoated and forms a pre-integration complex (PIC). The PIC is 
translocated across the nuclear pore during cell division and into the nucleus. Early 
phase infection is completed once the viral genome has been integrated into the host 
genome using the viral protein integrase (Nisole & Saïb, 2004). Infected resting 
memory CD4+T cells serves as a source of latent infection and supports continued 
HIV-1 vireamia (Kim & Perelson, 2006). The late phase is initiated by the expression 
and release of viral proteins from the nucleus and ends with the formation of new 
progeny virus. Once integrated, the body recognizes the foreign DNA as its own and 
begins the process of transcribing viral RNA. Spliced and unspliced mRNA 
transcripts are translocated across the nuclear pore and translated within the 
cytoplasm. Translated gag polyproteins are recognized by other viral and cellular 
components and collectively transported to the cell membrane where it is packaged 
into new virus progeny and released from the host cell by budding as immature viral 
progeny (Briggs et al., 2003; Freed, 2001). During or after the budding process, 
protease will induce structural changes and viral maturation via the proteolytic 
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processing of gag p55. Continuous immune activation results in host cell death via 
apoptosis, causing a severe loss of CD4+ T-cells (Roshal et al., 2001; (Badley et al., 
2003; Badley, 2005).  
                                   
Figure 1.4 HIV-1 viral life cycle. HIV-1 virus binds and fuses to host cell, fusion facilitates release of 
viral RNA and reverse transcription is initiated. Viral DNA translocates into nucleus and is integrated 
into host genome. The host cell transcribes viral DNA and immature viral proteins are assembled and 
released from host cell, where the virion develops into mature virus. (Source: 
http://upload.wikimedia.org/wikipedia/commons/3/35/HIV_gross_cycle_only.png ). 
 
1.1.4 Classification of HIV-1 
HIV can be divided into two types, HIV-1 and HIV-2. Phylogenetic analysis has been 
used to classify the virus and also identify the distribution pattern of these strains 
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across the world. HIV-2 originated from SIV/SMM infected sooty mangabeys 
(Cercocebus atys). It is exclusive to West and Central Africa. HIV-1 on the other 
hand can be found in various regions of the world. HIV-1 is further divided into four 
groups, M (major), O (outliers) and N (Non-M, non-O) which originated from SIV 
infected chimpanzees (Pan troglodytes troglodytes ) (Gao et al., 1999). In addition a 
newly discovered group P that originated from gorillas has been described (Plantier 
et al., 2009). The M group is responsible for most of the world’s HIV infection and 
can be divided into nine different subtypes (A-D, F-H, J and K) according to env 
gene diversity (Figure 1.5). Epidemiological studies have suggested that these 
subtypes each evolved from numerous founder viruses during epidemics in Africa 
and that this continued evolution eventually produced sub-subtypes and at least 55 
Circulating Recombinant Forms (CRF’s) (http://www.hiv.lanl.gov). CRF’s are 
identified according to a numerical system and letters which present their parental 
subtype (Ball et al., 2003; Tebit & Arts, 2011). In areas of subtype co-circulation, up 
to 10% of HIV-1 infections are a consequence of unique recombinant forms (URFs) 
(Pond and Smith 2009). A number of factors, such as dual HIV-1 infection, promote 
the emergence of URFs and unlike the slow accumulation of mutations through 
replication errors, this form of recombination causes rapid sequence diversity 
(Ragupathy et al., 20011).   
 
                
Figure 1.5 Classification of HIV-1. The classification of HIV and the various groups, subtypes and 
CRF’s of HIV-1 are indicated in the diagram. HIV-1 is shown to have 4 groups: M,N, O and P with the 
group M  sub-dived further into subtypes A, B, C, D, F, G, H, J, K and CRF’s.  
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1.2. HIV-1 diversity in South Africa 
In 1982 the first case of HIV-1 was documented in South Africa (Ras et al., 1983; 
Becker et al., 1985). The reported cases initially seemed to be localized amongst 
homosexual white men and were dominated by subtype B and subtype D. However 
by the beginning of the 1990’s heterosexual members of the indigenous African 
population were also infected by HIV-1 (Sher, 1989; Engelbrecht et al., 1995; 
Williamson et al., 1995). Heterosexual infections has since become the prevalent 
form of HIV-1 transmission, with subtype C as the main subtype circulating in 
infected South Africans. However, a number of non-subtype C viruses and 
recombinants have also been reported (Engelbrecht et al., 1995; Van Harmelen et 
al., 1997; Bredell et al., 2002; Papathanasopoulos et al., 2002; Loxton et al., 2005; 
Rousseau et al., 2006). A study by Jacobs et al., (2009) identified their cohort 
sequences as predominantly subtype C (89%) followed by subtype B (6.8%), 
subtype A (3.1%) non-subtype C’s (F1, G, U) and a CH recombinant. Another study 
which investigated the HIV-1 diversity of Cape Town between1984 and 2010 showed 
that earlier HIV-1 sequences consisted of subtype B, C and D sequences.  However 
later sequences were identified with a higher level of recombination and repeated 
detection of URFs (Engelbrecht et al., 2011).     
1.3 The Structural and functional importance of HIV-1 tat 
1.3.1 HIV-1 tat gene and Tat protein 
HIV-1 Tat is an early and late regulatory protein essential for HIV-1 replication. The 
protein is cationic in nature and exists in two forms made of 86 and 101 amino acids 
respectively. The dualistic form of Tat is generated by the translation of differentially 
spliced viral transcripts. However the exon 2 form of Tat appears to dominate early 
HIV-infection while the exon 1 form is produced after rev protein expression. 
Truncated forms of the protein appear to be viral strain dependant and have been 
shown to induce the same biological effects as the complete protein sequence 
(Buscemi et al., 2007; Amendt et al.,1994; Jeang et al., 1999). The truncated form 
(86 AA) is the most studied form of HIV-1 Tat and is predominantly found in HIV-1 
subtype B, while the 101 amino acid form of Tat can be found in subtype C and most 
other HIV-1 strains.  
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The Tat protein is between 14 and 16kDa in size and consists of 6 domains. The first 
5 domains are found within exon 1 and the 6th domain is found within exon 2 as 
illustrated in Figure 1.6. 
The N-terminal is the first domain (1-20 AA) and is said to tolerate mutations well. 
Domain 2 (21-40 AA) regulates Tat function, is highly conserved and contains 7 
cysteine’s. Mutations in this area render the protein non-functional. Domain 3 (41-48 
AA) is called the core domain and is essential for the transactivation activity of Tat. 
Domain 4 (49-57 AA) is the basic domain and is the most studied of all the domains 
and contains a conserved RKKRRQRRR motif. Domain 5 is called the glutamine rich 
domain (58-72 AA) while the remaining residues complete the C-terminal (73-101 
AA). The basic and C-terminal domains collectively confer Tat with TAR RNA binding 
capabilities which is necessary for both nuclear localization and the assimilation of 
Tat into cells (Buscemi et al., 2007; Jeang, 1996; Jeang et al., 1999; Pugliese et al., 
2005). Tat is also a mediator of HIV-1 neuro-pathogenesis and does so with the use 
of neurotoxic and chemotactic domains encoded within the first exon (Cowley et al., 
2010). 
 
 
Figure 1.6:  The domains of HIV-1 tat. The figure illustrates tat exon 1; tat exon 2 and the domains 
each are comprised of. The figure also highlights areas needed for integrin binding and nuclear 
localization and how many domains can sustain minimal or sufficient transactivation. (Adapted from: 
Kiebala, 2010).   
 
 
Stellenbosch University  http://scholar.sun.ac.za
23 
 
1.3.2 Activation of HIV LTR by Tat 
Early HIV LTR reporter gene studies showed that in the presence of Tat, 
transactivation activity was a hundred times higher than when Tat was absent (Cann 
et al., 1985). Tat has since been extensively studied and the mechanism of 
transactivation is well defined. Tat LTR activation was shown to be a RNA-
dependent process; however other mechanisms of LTR activation include the use of 
transcription factors such as NF-κB, Sp-1 and NF-IL6. In the presence of Tat the 
LTR will produce long viral transcripts that enhance viral activation and in the 
absence of Tat, short viral transcripts will be produced. The activation of the LTR 
commences with the recruitment of the RNA Polymerase II complex. This complex 
consists of mediators and a carboxyl-terminal domain (CTD) that blocks the 
activation of the LTR. Tat activates cyclin-dependent kinase 7 (CDK7), a component 
of the TFIIH complex, resulting in the phosphorylation of the CTD and the removal of 
the mediators. Transcription of the tat activation region (TAR) is initiated, resulting in 
the TAR RNA to form a stem loop structure which facilitates the attachment of the 
RNA binding domain. The process of Tat and TAR binding is driven by a kinase 
complex, consisting of trans-kinase 9 (CDK9) and cyclin T1, which forms a zinc-
dependent complex with Tat. CDK9 phosphorylates the CTD which relocates the 
TAR and allows the RNA polymerase to transcribe the HIV-1 genome (Karn, 1999)  
1.3.3 Production of Tat 
Since Tat is pivotal for HIV-1 infection it is expressed during the early stages of 
infection at low levels without the HIV genome being transcribed. Tat is also released 
from un-ruptured HIV-1 infected cells into the cell microenvironment (Arya et al., 
1985; Westerndorp et al., 1995; Xiao et al., 2000). It has been suggested that Tat is 
not secreted as a single peptide; it does not make use of the endoplasmic reticulum 
for protein secretion but a pathway similar to what Interleukin-1 beta (IL-1β) and 
Basic fibroblast growth factor (bFGF). It has been reported that in HIV-1 infected 
cultured supernatants approximately, 0.1 to 1 ng/ml of Tat can be produced 
(Westerndorp et al., 1995). In addition the levels of intact functional Tat detected in 
patient serum appear to be proportional to viral titers found in the circulation (Finzi & 
Siliciano, 1998). It has therefore been speculated that Tat production is directly 
proportional to the progression of HIV-1. In addition, other studies have shown that 
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extracellular Tat is able to up-regulate HIV-1 replication while anti-Tat antibodies are 
said to do the reverse (Zauli et al., 1996). These findings therefore give credence to 
the theory that extracellular Tat may play a role in the progression of AIDS.  
1.3.4 Cellular Uptake of HIV-1 Tat 
Studies have shown that HIV-1 Tat is easily assimilated by various cells and is able 
to bind to a number of cell receptors such as CD26 CXCR4; heparin sulfate 
proteoglycans and low-density lipoprotein. These cell receptors often undergo 
endocytosis in T-cells using one of four endocytosis pathways: clathrin-mediated 
endocytosis, caveolae, micropinocytosis or phagocytosis (Gutheil et al., 1994; Xiao 
et al., 2000; Tyagi et al., 2001). T-cells are reported to use the clathrin-dependent 
pathway, while Tat utilizes the alveolar endocytosis pathway and clathrin-dependent 
pathways. This illustrates Tat’s ability to utilize different cell receptors for cell entry 
(Fittipaldi et al., 2003; Rayne et al., 2004; Vendeville et al., 2004).  
1.3.5 HIV-1 Tat mediated gene expression 
The role of Tat is not limited to HIV-1 replication. It also plays a role in gene 
expression and is able to induce the expression of a number of cytokines. Tat is able 
to activate the TNF-α promoter which in-turn initiates the production of TNF-α and IL-
10. TNF-α is responsible for the induction of apoptosis and other cellular responses 
while IL-10 inhibits Th1 cytokines thereby favoring viral replication (Sawaya et al., 
1998; Badou et al., 2000). Furthermore, Tat is able to induce the expression of IL-6 
which has been reported to exacerbate HIV-1 associated infections in infected 
patients (Kelly et al., 1998). A number of studies have also implicated Tat in the 
induction and suppression of apoptosis and have shown Tat to activate cell survival 
genes such as Bcl-2 while simultaneously inhibiting the expression of tumor 
suppressor gene p53 (Li et al., 1995; Zauli et al., 1996).  
1.3.6 Apoptosis induction by HIV-1 Tat 
Apoptosis is a controlled series of cell deaths. In normal cells, apoptosis facilitates 
the sculpturing of tissues and organs and is a critical aspect of organism 
development (Bouillet & Strasser, 2002; Meier et al.2000). It ensures the 
maintenance of cell populations as cells are often produced in excess. It is therefore 
Stellenbosch University  http://scholar.sun.ac.za
25 
 
critical for homeostasis. In most instances, apoptosis is advantageous to an 
organisms life cycle, however, abnormalities in apoptosis regulation results in the 
development of various diseases including cancer (O'Connor et al., 2000; Romani et 
al., 2010; Strasser et al., 2000). Apoptosis is controlled by a number of cell signals, 
which induce one of two apoptotic pathways. The extrinsic pathway is triggered by 
external stimuli and ligands, which include toxins, cytokines and death receptors 
such as Fas/CD95. The intrinsic pathway is regulated by mitochondria and the 
release of apoptotic-inducing molecules such as cytochrome c (Bouillet & Strasser, 
2002; Romani et al., 2010). These cell signals can either actively induce apoptosis or 
inhibit the apoptotic process (Denault & Salvesen, 2002). Studies have identified four 
groups of compounds or cell signals which affect the apoptotic process and include 
caspases, adaptor proteins, members of the tumor necrosis factor receptor (TNF-R) 
super family and members of the Bcl-2 family (O'Connor et al., 2000; Strasser et al., 
2000). 
Tat induces the intrinsic pathway in various human cells by activating various 
apoptotic proteins. Tat activates caspase 3, caspase 8 and tumour necrosis factor-
related apoptosis-induced ligand (TRAIL), in human monocytes. Tat also induces 
apoptosis by activating TNF-α and Fas ligands (FasL/CD95) in astrocytes. The latter 
is also responsible for the depletion of CD4 B cells. Furthermore, Tat also associates 
with microtubules and induces mitochondrial apoptosis. Induction of microtubule 
stabilization by Tat is potentially pro-apoptotic as cells require constant 
polymerization and depolymerization of microtubules. The alteration of microtubules 
acts as a strong inducer of the intrinsic apoptosis pathway (Romani et al., 2010). 
Many human neurodegenerative conditions are accompanied by a reorganization of 
the neuronal cytoskeleton and as tat interacts with micro tubular networks this could 
possibly explain the occurrence of HIV-1 neuropathogenesis. Recruitment of various 
apoptosis-inducing proteins by Tat has suggested the ability of the transactivation 
protein to utilize numerous pathways and cells for the induction of apoptosis. 
(Ashkenazi, 2002; O'Connor et al., 2000; Romani et al., 2010).  
1.3.7 Apoptosis suppression by HIV-1 Tat 
Inhibition of apoptosis by Tat seems to be in conflict with its role as an apoptosis 
inducer. However, Tat has been shown to up-regulate B-cell lymphoma 2 (Bcl-2), an 
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anti-apoptotic protein in monocytes. Extracellular Tat can be absorbed by peripheral 
blood monocytes and induce BcL-2 to inhibit apoptosis by TRAIL. Tat also 
associates with B-cell lymphoma-extra large (Bcl-xl), another member of the Bcl2-
family and forms a compound capable of inhibiting apoptosis in neurons.The anti-
apoptotic properties of TAR could possibly explain how infected cells could inhibit 
apoptosis while extracellular Tat induces apoptosis. The anti-apoptotic activities of 
Tat could therefore cause the formation of HIV-1 latency in human cells, although 
Tat apoptosis in the CNS is complex (Romani et al., 2010). 
1.3.8 Mutations in tat exon 1 
Clade-specific differences in transmission and spread of the various subtypes have 
been documented. However, it is unclear if differences in biological properties may 
influence disease progression (Mishra et al., 2008). Studies conducted on subtype B 
and subtype C analyzed sequences on a genetic and molecular level and provided 
evidence that a point mutation (C30S31) of subtype C decreases the chemotactic 
functions of Tat. The mutation is not geographically limited and has been identified in 
a number of different subtype C strains as well as other non-subtype B sequences 
(Mishra et al., 2007). In addition, subtype C Tat differs from subtype B Tat due to a 
C31S mutation (Campbell et al., 2005; Contreras et al., 2005; Desfosses et al., 
2005). It has been reported that Tat is a chemo attractant for macrophages, 
monocytes and dendritic cells and induces chemotaxis via a CCR2-dependent 
mechanism that is dependent upon the integrity of the dicysteine motif of Tat. The 
cysteine-rich domain of Tat is reported to contain positions of amino acid similarity 
with β-chemokine critical for chemokine receptor binding and signal transduction. 
The C30S31 mutation terminates the ability of Tat to act as a chemo attractant by 
causing inhibition of the CCR2-dependant mechanism. Furthermore, Tat also exerts 
a neurotoxic effect on hippocampal neurons. Tat and neurocognitive impairment has 
been shrouded in controversy, but there is now evidence that Tat mediates 
neurotoxicity via its cysteine and basic domains. Yet, this is not the only route of 
inducing neurotoxicity. It can also exert a neurotoxic effect on neurons by uncoupling 
Ca2+ permeable N-methyl-D-aspartate (NMDA) receptors from Zn2+ inhibitors, 
thereby causing NMDA mediated death (Rao et al., 2008; Campbell & Loret, 2009). 
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In addition, Tat exon 1 contains a number of adjacent point mutations which may 
influence the transactivation and phosphorylation of the virus, summarized in Figure 
1.8 and Table 1.2 (Cowley et al., 2010). According to Jeang, 1996 the majority of 
mutations are concentrated within amino acids 1-58 However, analysis of mutations 
revealed that the first 21 amino acids are fairly tolerant of mutations while mutations 
in amino acids 22-40 was problematic and often detrimental for trans-activation. In 
contrast mutations in amino acids 49-57 did not significantly alter Tat function 
(Jeang, 1996).  
 
 
Figure 1.8: Summary of tat mutations identified in HIV-1 clade B sequences. A total of 17 
mutations were identified from the literature. The majority of these mutations have been associated 
with transactivation activity. (Source: Adaption of Kiebala, 2010 and Cowley et al., 2010).  
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Table 1.2 Significance of amino acid substitutions Tat exon 1 (Cowley et al., 2010). 
Amino Acid substitution Importance 
E2K E2 provides intermolecular hydrogen bond with K51 and 
R53 
W11* Stop codon, truncated Tat protein 
S16G S16 site of phosphorylation by CDK2, mutants 
associated with reduced transactivation 
C22Y C22 required for transactivation 
K28R K28 site of Tat acetylation by p300/PCAF, potentially 
decreased transactivation 
C31R C31 required for transactivation 
C34R C34 required for transactivation 
K41E K41 mutation reduces transactivation 
S46P S46 site of phosphorylation by CDK2, associated with 
reduced transactivation 
Y47H Y47H associated with reduced transactivation 
K50E K50 site of Tat acetylation by p300/PCAF, potentially 
decreased transactivation 
K51E K51 site of acetylation by p300/PCAF, potentially 
decreased transactivation 
R56Q Reduced TAR interaction and transactivation 
R57G Reduced TAR interaction and transactivation 
S62G S62 site of phosphorylation by PKR, associated with 
decreased TAR interaction 
T64N T64 site of phosphorylation by PKR, associated with 
decreased TAR binding 
T64D T64 site of phosphorylation by PKR, associated with 
decreased TAR 
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1.4 Neurocognitive complications of HIV-1 
1.4.1 HIV associated neurocognitive disease (HAND) 
According to Antinori et al. (2007), HAND can be divided into three categories: 
asymptomatic neurocognitive impairment (ANI), minor neurocognitive disorder 
(MND) and HIV-1 associated dementia (HAD). ANI and MND are the most frequently 
occurring forms of HAND and affect 30%-60% of HIV-1 infected individuals (Grant, 
2008). ANI is defined by subtle cognitive impairment and occurs during the early 
stages of HIV-1 infection and can last for up to 10 years. MND is similar to ANI 
however individuals experience mild impairments such as motor function and 
behavioral abnormalities which may affect daily activities.  
HAD occurs during the final stages of HIV-1 infection and is characterized by 
extreme difficulties in attention, concentration, speed of processing information, 
mental flexibility, verbal learning and memory, as well as motor speed (Gupta et al., 
2007; Grant, 2008).  
HAND has slowly become more prevalent in HIV-1 infected individuals and is a 
growing concern for the global HIV-1 population. A number of HAND cases have 
been reported in America and recently in South Africa as well. HAND has been 
described as a culmination of genetic and cellular factors such as neurotoxic proteins 
(gp41, Tat) and cytokines (IL-6 and TNF-α) which results in a varied spectrum of 
clinical manifestations (Ranga et al., 2004).  
1.4.2 Prevalence of HAND 
It is estimated that 15 000 new cases of HAND including ANI, MND and HAD are 
reported annually (Odiase et al., 2006). The prevalence of neurocognitive 
impairment has not been clearly defined as some studies have reported a 
prevalence of 5% while others have reported a prevalence of 20%. A study 
conducted in 2007 found that 60.5% of study participants experienced mild to 
moderate cognitive deficits associated with memory or learning (Gupta et al., 2007). 
Similarly, Grant (2008) reported that 50% of HIV-1 treatment-naive patients in their 
cohort as having a form of cognitive, behavioral or motor impairment.  
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1.4.3 HAART and HAND 
It has been reported that although Highly Active Anti-retroviral Therapy (HAART) 
effectively dampens the symptoms of HAND it is unable to prevent the eventual 
onset of the neurological disorder (Tardieu, 1999). The CNS acts as a reservoir for 
the virus replication even during maximal treatment with HAART. It is therefore not 
surprising that HIV-1 associated neurocognitive disorders persist (Boissé et al., 
2008; Jevtović et al., 2009). However HAND is not fully understood and various 
mechanisms have been implicated in the progression and severity of the disease 
(Mishra et al., 2008).  
HAART, a combination therapy, consisting of three classes of drugs: protease 
inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and non-
nucleoside reverse transcriptase inhibitor (NNRTI) is said to lower the symptoms of 
HAND although its effects are disputable for a number of reasons (Parsons et al., 
2006; Sacktor et al., 2006). Due the protective nature of the blood brain barrier 
(BBB) the CNS is not easily accessible to invasive chemicals such as antiretroviral 
drugs (Lin et al., 1996; Brew, 2001). Due to the highly protein-bound nature of PI, 
very little or none of them are translocated across the BBB. NRTIs and NNRTIs have 
displayed moderate penetration of the BBB but only at hematologic intolerable doses 
(Brouwers et al., 1997; Gisslén et al., 1997; Brew, 2001).  
1.4.4 HAND and HIV-1 subtypes 
A number of studies have suggested that the severity and prevalence of HIV-1 
associated cognitive impairment are clade specific (Sacktor et al., 2006; Mishra et 
al., 2008). It has been proposed that cognitive impairment especially HAD is most 
prevalent in subtype B due to the presence of the C30C31 mutation in the Tat motif. 
However, one would expect more HAND in sub Saharan Africa especially given the 
frequency of opportunistic infections such as tuberculosis, malaria and poverty to 
complicate existing HIV-1 infection (Sacktor et al., 2006). In addition subtype C is 
also responsible for more than 50% of the world’s HIV-1 infections particularly in 
developing countries such as India, Africa and China (Liner et al., 2007; Valcour, et 
al., 2007). Studies conducted in India proposed that subtype C was associated with 
reduced levels of cognitive impairment than subtype B as none of the study 
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participants presented with any symptoms of HAD (Chandra et al., 2006; Gupta et 
al., 2007). However a study conducted in Cape Town, South Africa found subtype C 
HIV- 1 associated cognitive impairment to be prevalent with HAD manifesting in 
23.5% of the study participants (Joska et al., 2010). This reinforces Sacktor et al.'s, 
(2005) claim that HAD may become the leading cause of dementia in young adults. 
1.4.5 Role of HIV-1 Tat in HAND  
A growing amount of evidence has cemented the link between HAND and HIV-1 Tat, 
which has been described as a toxic protein capable of inducing apoptosis via a 
multitude of pathways. Tat is able to easily enter various cell types including T and B 
cells, as well as cells of the CNS (Pu et al., 2003). The release of Tat by infected 
cells results in the increase of TNF-α, induction of oxidative stress in the cellular 
environment and the migration and adhesion of endothelial cells activated with T 
helper-1 type inflammatory cytokines. It also results in the activation of caspases and 
ultimately apoptosis of neurons. The induction of oxidative stress is most likely a 
product of excess Ca2+ in neurons and the production of reactive oxygen species 
(ROS) by mitochondrial calcium uptake. Oxidative stress has been speculated to be 
a major cause of neurodegenerative diseases and has been detected in both the 
brain and cerebrospinal fluid (CSF) of HAND patients (Pu et al., 2003; Buscemi et 
al., 2007; Romani et al., 2010).   
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AIMS AND OBJECTIVES OF THE STUDY 
The aims of this project was to subtype HIV-1 in the Cape Town cohort being 
investigated for HAND with a special focus on characterizing the HIV-1 tat gene and 
Tat protein in vitro.  
The specific objectives were to:  
1. Subtype HIV-1 in the patient cohort. 
2. Characterize the HIV-1 tat gene in the HAND cohort and identify mutations in 
the C30C31 position. 
3. Construct recombinant tat clones and investigate the apoptotic ability of the 
clones in cell culture.  
To achieve the first objective, HIV-1 nucleic acids were isolated, amplified, 
sequenced and subtyped using phylogenetic analysis as described in Chapter 2. 
The Tat sequences obtained from the HAND cohort were then further analyzed and 
compared with different subtype B and subtype C datasets (Chapter 3).  
Specific mutations observed in the C30C31 position were then used to construct 
recombinant clones in an inducible CMV expression vector. After transfection of 
293T cells with the clones, the subsequent expression of Tat protein was assessed 
with flow cytometry to determine the apoptotic ability of each mutation (Chapter 4). 
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CHAPTER TWO 
HIV-1 genetic diversity: Molecular characterization of partial gag, pol, 
accessory and gp41 fragments 
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2.1. Introduction 
In this chapter the subtyping of the HIV-1 strains in the cohort are described. Briefly, 
after the isolation of viral RNA and proviral DNA, the nucleic acids were used as 
templates for the amplification of different genomic regions of the partial gag; pol; 
accessory and gp41 genes. Pre-nested (first round) RT-PCR assays were used for 
the reverse transcription of RNA and amplification of cDNA and PCR were used for 
first round amplification of DNA. After nested (second round) PCR, the amplified 
gene fragments were visualized with agarose gel electrophoresis and directly 
sequenced. Sequences were verified and used in the phylogenetic analysis of the 
different HIV-1 genes. An overview of the different techniques used, is indicated in 
Figure 2.1.  
 
Figure 2.1: Overview of steps used to determine HIV-1 subtypes and genetic 
diversity.  
Stellenbosch University  http://scholar.sun.ac.za
36 
 
2.2. Materials and Methods 
2.2.1 Reagents and equipment  
All the reagents, equipment, and software applications that were used during the 
course of this study are listed in Tables 2.1 - 2.3. Registered trade mark items and 
trade mark products are indicated by the symbols ® and TM respectively. 
Table 2.1. List of chemicals and kits used in the study. 
Chemical or Commercial products and 
kits used 
Supplying Company 
QIAamp Viral RNA Mini Kit QIAGEN, Dusseldorf, Germany 
QIAamp DNA Blood Mini Kit QIAGEN, Dusseldorf, Germany 
Access RT-PCR System Promega, Madison, WI, USA 
GoTaq® DNA Polymerase Promega, Madison, WI, USA 
dNTP´s  Promega, Madison, WI, USA 
Nuclease free water Promega, Madison, WI, USA 
Agarose Whitehead Scientific (Pty) Ltd. 
Ethidium Bromide Promega, Madison, WI, USA 
6x Blue Orange Loading Dye Promega, Madison, WI, USA 
QIAquick PCR Purification Kit QIAGEN, Dusseldorf, Germany 
BigDyeTM Terminator sequence Kit Applied BioSystems, CA, USA 
5x Sequencing Buffer Applied BioSystems, CA, USA 
BigDye XTerminator Purification Kit Applied BioSystems, CA, USA 
Exonuclease (Exo I) Affymetrix, OH, USA 
Shrimp alkaline phosphate Affymetrix, OH, USA 
ExoSAPIT Affymetrix, OH, USA 
1Kb DNA Ladder Promega, Madison, WI, USA 
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Table 2.2. Equipment used to perform sample analysis. 
Piece of Equipment Supplying Company 
QIAcube nucleic acid isolation 
system 
QIAGEN, Dusseldorf, Germany 
GeneAmp PCR System 9700 thermal 
cycler 
Applied BioSystems, CA, USA 
Hoeffer EPS 2 A 200, Power Pack Pharmacia Biotechnologies, CA, USA 
SyngeneTM GeneGenius Computer 
System 
Synoptics Ltd., Cambridge, UK 
ABI 3130xl automated Genetic 
analyser 
Applied BioSystems, CA, USA 
NanodropTM ND 1000 Nanodrop Technologies  Inc. 
Delaware, USA 
Techne®   Gene E Thermal Cycler Techne Ltd.  Cambridge, UK 
 
Table 2.3. Software programs and online tools that were used in sequence analysis. 
Software package References and/or licensed companies 
Sequencher v 4.8 Gene Codes Corporation, Ann Arbor, MI, USA 
ClustalW v 2.1 Thompson© et al, 1997 
LANL QC Los Alamos National Security, USA 
REGA v 3.0 HIV subtyping tool de Oliveira et al., 2005 
jpHMM Spang et al., 2002 
SQUEAL Pond et al., 2009 
Stanford Rhee et al., 2003 
MEGA 5.1 Tamura et al., (2011) 
Geneious Biomatters Ltd, Auckland, NZ 
CPR Gifford et al., 2009 
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2.2.2 Patient samples  
Patients (n = 64) were enrolled from 3 clinics in the Cape Town area and were 
assigned numbers to ensure confidentiality e.g. (JO198). Stored samples were kindly 
provided by Prof. John Joska (UCT) and consisted of 2ml Peripheral Blood 
Mononuclear Cells (PBMCs) and 6ml of plasma for each patient. Samples were 
stored at -20oC until used for nucleic acid extractions. 
 
2.2.3 Nucleic acid extractions 
Viral RNA extractions:  
RNA was extracted from 140µl of plasma using the QIAamp mini viral kit (Qiagen 
GmbH, Hilden, Germany) using the QIAGene QIAcube automated extraction system. 
The kit protocol was followed and RNA was eluted in 60µl of low salt buffer AVE. 
The Qiagen RNA extraction makes use of a silica-gel membrane principle developed 
by Vogelstein and Gillespie (1979). Lysing buffer is added to patient plasma to 
degrade the viral capsid and to release nucleic acids, which are then bound to a 
silica membrane within a QIAamp spin column during centrifugation. Residual 
contaminants were removed from the silica membrane with wash steps to ensure the 
purity of the sample. Salt and pH conditions help to retain nucleic acids within the 
silica membrane and ensure that they could only be eluted with water or low salt 
buffers. Isolated RNA was used for the molecular characterization of gag p24 and 
pol gene fragments. 
 
Proviral DNA extractions:  
DNA was extracted from 200µl PBMCs using the QIAamp DNA blood mini kit 
(Qiagen GmbH, Hilden, Germany) using the QIAGene QIAcube automated 
extraction system. The kit protocol was followed and DNA was eluted in 100µl of low 
salt buffer AE. Isolated DNA was used for the molecular characterization of the 
accessory gene and gp41 gene fragments. 
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2.2.4 Polymerase chain reactions   
All samples were amplified for the four gene regions: gag, pol, accessory genes and 
gp41 as indicated in Figure 2.2.  
              
Figure 2.2 Amplified gene fragments. Four gene fragments were amplified for patient samples partial 
gag (484bp), pol (1.2kb) accessory (1.3kb) and gp41 (388bp) genes. Region and size of amplified 
fragments are indicated by lines on HXB2 scale.  
 
2.2.4.1 Partial Gag RT-PCR 
A total of 5µl of RNA was used for pre-nested (first round) gag p24 reverse 
transcriptase polymerase chain reaction (RT-PCR). The RNA was converted to 
cDNA by using the Access RT-PCR system (Promega, USA) and then used as the 
template in a one-step PCR reaction.  
The primer pairs used for pre-nested and nested gag amplification are described in 
Table 2.4 and were used at a final concentration of 40 pmol. Final concentrations of 
the remaining reagents were as follows: 0.2mM dNTP’s, 1mM MgSO4, 1.1U AMV/ 
Tfl, 1X reaction buffer and 1.1U AMV reverse transcriptase. Nuclease-free water was 
added to a final volume of 50µl. A second nested PCR was performed, using 3µl of 
the pre-nested PCR product as template. The final concentrations of reagents for 
nested PCR reaction were as follows 0.2mM dNTPs, 1.5mM MgCl2, X1 GoTaq Flexi 
buffer, 0.05U Taq DNA polymerase, water was added to a final volume of 50µl per 
reaction. The Gene Amp® 9700 PCR system (Applied Biosystems, USA) was used 
for the amplification of gag fragments with cycling parameters described in Table 2.5  
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Table 2.4. Primers used in the amplification of the partial HIV-1 gag gene products. 
 
Primer Oligonucleotide sequence F/R HXB2  
Location 
TM (°C) 
cDNA and 
first round  
p24-7 CCCTGRCATGCTGTCATCA R 1826←1844 55.2 
p24-1 AGYCAAAATTAYCCYATAGT F 1174→1193 56.3 
Nested PCR p24-2 AGRACYTTRAAYGCATGGGT F 1237→1256 50.0 
p24-6  TGTGWAGCTTGYTCRGCTC R 1703←1721 50.0 
 
Table 2.5 Cycling parameters of gag p24 PCR 
Cycling conditions for the PreNested gag p24 PCR assay 
Step Temperature Duration Cycles 
Reverse Transcription  48°C 45 min x1 
Initial Denature Step 94°C 2 min x1 
Denature 94°C 20 sec 
x40 Anneal 45°C 30 sec 
Extend 68°C 90 sec 
Final Extension 68°C 10 min x1 
Cycling conditions for the Nested gag p24 PCR assay 
Step Temperature Duration Cycles 
Initial Denature Step 94°C 2 min x1 
Denature 94°C 20 sec 
x40 Anneal 50°C 30 sec 
Extend 68°C 60 sec 
Final Extension 68°C 10 min x1 
sec – seconds; min – minutes; °C – Degrees Celsius 
 
2.2.4.2 Partial Pol RT-PCR 
The PCR procedures described in Section 2.3.1 was repeated for the pol gene with 
5µl of RNA being used for the pre-nested pol RT-PCR reaction and 3µl of this 
product being used as template for the nested PCR. Concentrations of reagents and 
primer pairs were the same as described before. The primer pairs and cycling 
parameters are described in Tables 2.6 and 2.7 respectively.  
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Table 2.6: HIV-1 pol gene amplification primers 
 
Primer Oligonucleotide sequence F/R HXB2  
Location 
TM 
(°C) 
cDNA and 
first round  
PR-5′ 
prot -1 
TAATTTTTTAGGGAAGATCTGGCCTTCC F 2082→2109 57.0 
RT-MJ4 CTGTTAGTGCTTTGGTTCCTCT R 3399←3420 55.0 
Nested 
PCR 
PR-5′ 
prot-2 
TCAGAGCAGACCAGAGCCAACAGCCCCA F 2136→2163 68.0 
RT-
NE135 
CCTACTAACTTCTGTATGTCATTGACAGTCCAGCT R 3300←3334 62.0 
 
Table 2.7: Cycling parameters of pol PCR 
Cycling conditions for the PreNested RT-pol PCR assay 
Step Temperature Duration Cycles 
Reverse 
Transcription  65°C 30 sec x1 
Initial Denature Step 94°C 2 min x1 
Denature 94°C 20 sec 
x40 Anneal 56°C 30 sec 
Extend 68°C 90 sec 
Final Extension 68°C 5 min x1 
Cycling conditions for the Nested RT-pol PCR assay 
Step Temperature Duration Cycles 
Initial Denature Step 94°C 2 min x1 
Denature 94°C 30 sec 
x40 Anneal 65°C 30 sec 
Extend 68°C 60 sec 
Final Extension 68°C 7 min x1 
 
2.2.4.3 Accessory genes PCR 
The PCR amplified a sub-genomic region encompassing five genes namely vpr, vif, 
tat, rev and vpu using 5µl of proviral DNA for the pre-nested PCR and 3µl of this 
product for the nested PCR. Both pre-nested and nested PCR’s were performed 
using the Promega GoTaq Flexi ® kit (Promega, USA) and contained 0.2mM dNTP’s, 
1.5mM MgCl2, X1 GoTaq Flexi buffer, 1.1U Taq DNA polymerase and nuclease free 
water in a final volume of 50µl. Primers for both pre-nested and nested PCR’s are 
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summarized in Table 2.8 and were used at a final concentration of 40pmol. Cycling 
parameters for both PCRs are described in Table 2.9. 
 
Table 2.8: Summary of primers used for the accessory gene amplification 
 
Primer Oligonucleotide sequence F/R HXB2  
Location 
TM (°C) 
cDNA and 
first round  
FGF46 5' -GCA TTC CCT ACA ATC CCC AAA G-3' F 4648-4669 56.1 
ES8X 5' -CAC TTC TCC AAT TGT CCC TCA-3' R 7668-7648 55.7 
Nested PCR N817 5' -TCT GGA AAG GTG AAG GGG CAG T-3' F 4954-4975 60.7 
N1156 5' -TCA TTG CCA CTG TCT TCT GCT CT-3' R 6206-6228 58.5 
 
Table 2.9 Cycling parameters of accessory gene amplification 
Cycling conditions for the PreNested RT-pol PCR assay 
Step Temperature Duration Cycles 
Initial Denature Step 94°C 2 min x1 
Denature 94°C 30 sec 
x40 Anneal 55°C 30 sec 
Extend 68°C 3 min 
Final Extension 68°C 10 min x1 
Cycling conditions for the Nested RT-pol PCR assay 
Step Temperature Duration Cycles 
Initial Denature Step 94°C 2 min x1 
Denature 94°C 30 sec 
x40 Anneal 55°C 30 sec 
Extend 68°C 90 sec 
Final Extension 68°C 7 min x1 
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2.2.4.4 Partial env gp41 PCR 
Partial env gp41, including the tat exon 2 and rev exon 2 fragments, were amplified 
using primers described in Table 2.10 at a final concentration of 40pmol.  
Concentrations of pre-nested and nested PCR reactions were as follows: 0.2mM 
dNTP’s, 1.5mM MgCl2, X1 GoTaq Flexi buffer, 1.1U Taq DNA polymerase and 
Nuclease free in a final volume of 50µl. All PCR’s were performed on the GeneAmp® 
9700 PCR system (Applied Biosystems, USA) using 5µl and 3µl of DNA for pre-
nested and nested PCR’s respectively. Cycle parameters have been summarized in 
Table: 2.11. 
 
Table 2.10. Summary of primers used for the amplification of gp41 gene fragments. 
 
Primer Oligonucleotide sequence F/R HXB2  
Location 
TM (°C) 
cDNA and 
first round  
N1169 5'-AAT ATT CAT AAT GAT AGT AGG AGG-3' R 8273-8296 47.4 
N847 5'-TTA TTG CAA AGC TGC TTC AAA GCC CTG TC-3' F 8767-8795 61.6 
Nested PCR Rev X2R 5'-TCCTATCTGTTCCTTCAGCTA-3' R 8709-8689 60 
Rev X2F 5'-TGCTGTGCTCTCTATAGTRA-3' F 8321-8340 55 
 
Table 2.11. Cycling parameters of gp41 gene fragment amplification 
Cycling conditions for the PreNested RT-pol PCR assay 
Step Temperature Duration Cycles 
Initial Denature Step 94°C 2 min x1 
Denature 94°C 30 sec 
x40 Anneal 43°C 30 sec 
Extend 68°C 1 min 
Final Extension 68°C 7 min x1 
Cycling conditions for the Nested RT-pol PCR assay 
Step Temperature Duration Cycles 
Initial Denature Step 94°C 2 min x1 
Denature 94°C 30 sec 
x40 Anneal 50°C 30 sec 
Extend 68°C 60 sec 
Final Extension 68°C 7 min x1 
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2.2.5 Gel electrophoresis and purification of amplified fragments 
Partial gag, pol, accessory gene fragments were visualized using 0.8% to 1% 
agarose gel electrophoresis. Tris-Acetate-EDTA (TAE) buffer (0.04 M Tris acetate, 
0.001 M EDTA) was used to prepare agarose gels. DNA was stained with 5µl of 
ethidium bromide (0.5 µg per ml; Promega, USA) in a total volume of 50ml TAE 
buffer (1X). The marker used was a 1kb molecular weight DNA marker (Promega, 
USA) and also included was a negative and a positive control (sample previously 
positively amplified). DNA fragments were visualized with the UVItec Alliance 
Chemilluminscence and Fluorescence gel imaging system (Cambridge, UK). The 
expected fragment sizes for gag p24, pol, accessory gene and gp41 gene fragments 
were 484bp 1.2kb, 1.3kb and 388bp respectively. Visualized PCR products were 
purified using one of two methods, described below. 
Purification of gel fragments using Exonuclease 1 (Exo) and Shrimp Alkaline 
Phosphate (SAP) 
The first method utilized the enzymes Exonuclease 1 (Exo) and Shrimp Alkaline 
Phosphate (SAP) (USB Corporation, USA). A 10ul aliquot of the PCR products was 
placed into a 0.2-ml thin-walled PCR tube containing 0.5µl of SAP (1 U/µl) and 0.5µl 
Exonuclease (1 U/µl). These enzymes are able to degrade any substances which 
may inhibit the sequencing process. The SAP dephosphorylates the remaining 
deoxynucleotides and the exonuclease degrades primers and hydrolyses single 
stranded DNA. A Techne® Gene E Thermal cycler (Techne Ltd., UK) was used to 
incubate the reaction for 15 minutes at 37ºC. The enzymes were then inactivated at 
80ºC for 15 minutes. Purified samples were stored at 4ºC before sequencing 
reactions were performed. The Exo / SAP method has been labeled as a very crude 
method of DNA purification and therefore a second method was also used for the 
larger fragments.  
Purification of gel fragments using the SV gel and PCR clean-up system 
The second method made use of the Wizard SV gel and PCR clean-up system 
(Promega, USA). Approximately 10µl of the PCR product was mixed with an equal 
volume of membrane binding solution and transferred to a Wizard SV mini-column. 
Remaining PCR product was stored at -20ºC if purification was insufficient. DNA was 
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bound to the spin column membrane by centrifugation and washed twice to remove 
any impurities that may still be present. DNA was eluted with 50µl of nuclease free 
water.  DNA concentrations were determined using the Nanodrop™ ND-1000 
system (Nanodrop Technologies Inc.; USA) using 1µl of DNA. DNA concentrations 
are determined by measuring the sample absorbance (A) at a wavelength of 260 nm. 
The system can also determine the purity of the sample by dividing the absorbance 
at 260 nm by the absorbance of the sample at 280 nm. A purity reading between 1.7 
and 1.9 is indicative of pure DNA which is free of contaminants and proteins 
(Sambrook et al.,1989) (Ausubel et al, 2003).   
2.2.6 Sequencing of the amplified fragments 
Amplifiable gag and pol gene fragments were directly sequenced at a concentration 
of 50ng /µl while accessory gene and gp41 gene fragments were sequenced at a 
concentration of 20ng/ul. Primer pairs used for the sequencing reactions are 
summarized in Table 2.12 and were diluted with nuclease free water (Promega, 
USA) to a concentration of 5pmol/µl and used together with the BigDye™ Terminator 
v3.1 Cycle Sequencing Ready Reaction Kit (Applied Biosystems, USA). Each 
sequencing reaction consisted of 1.3µl of BigDye Terminator Enzyme Mix, 2.7µl of 
Half Dye (Bioline USA Inc., USA), 1µl of primer, 1µl of purified DNA and 4µl of 
nuclease free water (Promega, USA) to a final volume of 10µl. Cycling parameters 
are indicated in Table 2.13.  
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Table 2.12: Summary of primers used for the sequencing of fragments. 
Primers and Cycling conditions used for the sequencing of gag p24 PCR products 
Primer Forward / Reverse Annealing Temperature Reference 
gag p6 Reverse 53°C Swanson et al., 2003 
gag p2 Forward 53°C Swanson et al., 2003 
Primers and Cycling conditions used for the sequencing of pol PCR products 
Primer Forward / Reverse Annealing Temperature Reference 
JA 217 Reverse 60°C Plantier et al., 2005 
30 prot 2 Reverse 60°C Plantier et al., 2005 
Pol 1D Forward 60°C A Loxton personal communication 
AK 10 Forward 60°C Plantier et al., 2005 
AK 11 Forward 60°C Plantier et al., 2005 
pol 3 Forward 60°C S Engelbrecht personal communication 
NE 135 Reverse 60°C Plantier et al., 2005 
Primers and Cycling conditions used for the sequencing of accessory PCR products 
Primer Forward / Reverse Annealing Temperature Reference 
Vpr R1 Reverse 55 S Engelbrecht personal communication 
Vif 1F Reverse 55 S Engelbrecht personal communication 
N111 
N1156 
Forward                      
Forward 
                    55 
                    55 
Dr V Prasad personal communication 
Dr V Prasad personal communication 
Primers and Cycling conditions used for the sequencing of env gp41 PCR products 
Primer Forward / Reverse Annealing Temperature Reference 
Rev X2R Reverse 50°C S Engelbrecht personal communication 
RevX2F Forward 50°C S Engelbrecht personal communication 
 
Table 2.13 Sequencing cycle parameters 
 Temperature Time Cycles 
Denaturation 96 ºC 10 seconds 
 
25 X 
 
Annealing      ºC* 5 seconds 
Extension 60 ºC 4 minutes 
*Annealing temperatures for sequencing primer sets were indicated in Table 2.12.  
 
Gag and pol fragments were sequenced at the Central Analytical Facility at the 
Stellenbosch University, while accessory gene and gp41 gene fragments were 
sequenced at the Department of Pathology at the Division of Medical Virology. The 
latter sequences were purified using the BigDye XTerminator Purification Kit and 
analyzed on an ABI 3130XL genetic analyser (Applied Biosystems, USA). This is a 
polymer-based capillary electrophoresis sequencer connected to a computer which 
uses sequencing analysis software (Applied Biosystems, USA) and captures raw 
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data trace files. Raw data trace files were retrieved from the Central Analytical 
Facility and the 3130XL ABI Prism genetic analyser and imported into Sequencher 
4.8 (Gene Codes Corporation, USA). Low quality sequence ends were removed from 
overlapping nucleotide sequences to improve the quality of the sequences before 
being assembled into a single contig file. Assembled contig files were screened for 
ambiguities, edited and exported and saved in fasta format as a text file (.txt).  
2.2.7 Sequence quality control 
The online Quality control tool was used to examine the sequence sets for common 
problems: http://www.hiv.lanl.gov/content/sequence/QC/index.html Results from the 
tool include: subtype (from RIP), similarity (from HIV BLAST), phylogenetic (from 
Neighbor TreeMaker), stop codons and frameshifts (from GeneCutter) and 
hypermutation (from HyperMut).  
 
2.2.8 HIV-1 characterization using online subtyping tools 
2.2.8.1 Rega 3.0 subtyping analysis  
REGA (http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0.2/hiv/typingtool#/ ) is an 
online subtyping tool which utilizes phylogenetic analysis and bootscanning methods 
to screen sequences for recombination and subtype specific gene fragments. The 
genetic subtyping tool REGA 3.0 is able to analyses 1000 sequences at any given 
time and was used to analyses patient sequences and identify HIV-1 subtypes in the 
cohort (de Oliveira et al., 2005). 
2.2.8.2 Jumping profile Hidden Markov Model Analysis 
The jumping profile Hidden Markov Model (jpHMM) (http://jphmm.gobics.de/ ) 
method compares query nucleic acid or protein sequences to a family of sequences 
in a jumping alignment approach as proposed by (Spang et al., 2002). A single query 
sequence is therefore aligned and compared to different sequences of a single 
alignment. This approach simplifies the identification of recombinant events as 
breakpoints of recombinant isolates will be compared to different sequences in the 
alignment (Zhang et al., 2006; Schultz et al., 2009).  
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2.2.8.3 Subtype Classification Using Evolutionary Algorithms  
Frequent recombination events have lead to the formation of different CRFs and 
URFs. Although many subtyping software exists to identify new genetic mosaics, few 
are used to identify inter-subtype recombination. Subtype Classification Using 
Evolutionary Algorithms (SCUEAL) analysis detects recombination in multiple 
sequence alignments and identifies breakpoints, recombinant lineages and subtypes 
http://www.datamonkey.org/dataupload_scueal.php. This computational technique 
provides a more precise characterization of HIV-1 strains and is particularly useful 
for identifying novel recombinants. SCUEAL analysis is only available to analyze pol 
sequences for intra and inter clade recombination.   
 
2.2.9 Phylogenetic Analysis using MEGA  
2.2.9.1 Multiple Alignments of query and reference sequences 
Reference sequences were retrieved from the LANL (http://www.hiv.lanl.gov/) 
database for the gag gene (1237-1721bp, HXB2), the pol gene (2136-3335 bp, 
HXB2), the accessory genes (4954-6228 bp, HXB2) and the gp41gene (8321-8709 
bp, HXB2) fragments. Reference sequences from the 2010 dataset and query 
sequences were aligned in Clustal X v2.1 (Thompson et al., 1997). The multiple 
alignments were converted to Mega format (.meg). All reference sequences were 
labeled only with the family subtype and GenBank Accession number.  
2.2.9.2 Construction of Neighbor-joining trees 
Converted MEGA files (.meg) were analyzed in MEGA v5.1 (Tamura et al., 2011) 
and Neighbor-Joining trees were constructed with Kimura-2 parameter method of 
distance estimation (Kimura, 1980). Kimura 2 parameter is a method for inferring 
evolutionary distance in which transitions and transversions are treated separately. 
The accuracy of the generated tree was validated by bootstrap analysis with total of 
500 bootstrap replicates for each dataset, in other words the dataset was resampled 
and trees redrawn to achieve confidence levels indicated on neighbor-joining trees. 
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Confidence levels of 70% and greater were considered as significant (Felsenstein, 
1985).  
2.2.10 Analysis of resistance mutations within patient cohort 
The HIV-pol gene produces proteins which are pivotal for the maturation of viral 
progeny, an important step of HIV-1 replication and is therefore an attractive target 
for ARV therapies. It is also closely associated with drug resistance mutations (DRM) 
and was therefore cohort sequences were submitted to the HIVdb Program: 
Sequence Analysis program and analyzed for resistance mutations 
(http://hivdb.stanford.edu/). The HIVdb program receives query protease and RT 
sequences, and identifies levels of resistance to 20 commonly used protease and RT 
inhibitors.  
In addition to this pol sequences were also analyzed with the Calibrated Population 
Resistance (CPR) Tool version 6. (http://cpr.stanford.edu/cpr.cgi). CPR uses a list of 
surveillance drug resistant mutations (SDRM) endorsed by the World Health 
Organization (WHO) to identify transmitted resistance. The CPR program generates 
a profile alignment using FASTA-formatted sequence data and compares them to a 
consensus subtype B sequence. SDRM’s are used as markers to identify transmitted 
resistance in query sequences in the three classes of antiretroviral drugs: PI’s, 
NRTI’s and NNRTI’s (Gifford et al., 2009).  
 
 
2.3. Results 
2.3.1 Patient demographics 
The cohort of 64 patients consisted of both males and females investigated for 
HAND. A summary of the clinical information and patient demographics are provided 
in Table 2.14.  The complete patient information and demographics are listed in 
Appendix A. 
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Table 2.14: Patient information and demographics 
 
Variable Total study population (n=64) 
Age 
Range 21-36years 
Mean  30years 
Gender 
Male 17 (27%) 
Female 45 (70%) 
Unknown gender 2 (3%) 
HAND status 
No HAND 18 (28%) 
ANI 4 (6%) 
MND 26 (41%) 
HAD 11 (17%) 
Unknown 5 (8%) 
 
2.3.2 Nucleic acid extractions 
DNA and RNA were isolated from patient PBMCs and plasma respectively. A good 
DNA concentration level was obtained for all patient samples and ranged between 
45.06ng/µl and 192.89ng/µl. The purity levels of all samples were good with most 
being above 1.80 (260/280).  
2.3.3 Polymerase chain reactions and gel electrophoresis  
Fifty seven (89%) of the cohort samples were amplifiable for the 484bp fragment of 
the gag gene. However, for the pol gene only 47 (73%) of the cohort samples were 
amplifiable and generated DNA fragments of approximately 1.2 kb in length. 
Although dithiothreitol (DTT) was added to the PCR reaction to increase specificity, 
the amplifiability of the pol PCR was significantly lower than that of the gag PCR and 
is possibly due to the genetic variability of the cohort and length of the fragments.  
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For the 1.3kb accessory gene fragment, 51 (80%) samples could be amplified while 
for the 388bp gp41 gene fragment, 48 (75%) samples could be amplified. A 
summary of the PCR results are listed in Table 2.15. 
Table 2.15 Summary of the PCR results for the different fragments 
 RNA DNA 
 
gag pol accessory gp41 
N=sample 64 64 64 64 
% Positive 57 (89%) 47 (73%) 51 (80%) 48 (75%) 
% Negative 7 (11%) 17 (27%) 13 (20%) 16 (25%) 
 
All the amplified fragments were visualized by gel electrophoresis. A representative 
gel is presented in Figure 2.3., in which 12 partial gag fragments were visualized 
along with a positive control and NTC (non-template control). Samples JO161, 
JO254 and JO258 could not be amplified, however bright single DNA bands were 
obtained for the remaining 9 samples. 
   
 
Figure 2.3: Partial gag gene fragments amplified in nested PCR assay. After two rounds of 
amplification the 484bp is visualized on a 1% agarose gel. Twelve samples were visualized on the 
agarose gel along with a 1kb molecular marker (M), lane 1 (JO229), lane 2 (JO230), lane 3 (JO161), 
lane 4 (JO129C), lane 5 (JO240), lane 6 (JO238), lane 7 (JO248), lane 8 (JO247), lane 9 (JO252), 
lane 10 (JO254), lane 11 (JO258), lane 12 (JO259), Positive control (+C), and Non-template control 
(NTC).  
 
 M      1        2        3        4        5        6        7        8       9      10      11     12       +C     NTC        
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2.3.4 Sequence quality control  
Sequences quality control identified all gag genes as subtype C, except JO162, 
JO180, JO201 and JO209. A subtype could not be assigned to JO239. Sample 
JO162 was identified as an A1C recombinant however HIV-1 blast results identified 
the sample as a subtype C. The samples JO201 and JO209 were both identified as 
A1 subtypes. HIV-1 blast confirmed JO201 as an A1 subtype with from Sweden 
however JO209 was identified as a CRF06_cpx from the Niger.  
Analysis of pol sequences identified JO201 as an A1 subtype, JO209 as a G subtype 
and JO224 as a C/F1/G recombinant. HIV-1 blast identified AM041053 (subtype A) 
from DRC, FN599730 (CRF06_cpx) from Senegal and FJ199751 (subtype C) from 
South Africa as the most closely related sequences for JO201, JO209 and JO224 
respectively. 
Accessory gene analysis identified 2 samples as possible recombinants. Sample 
JO207 was identified as an A1/G recombinant with JO403028 (subtype B) from 
Switzerland as its closest relative. Sample JO286 was identified as a C/H 
recombinant but HIV-1 blast identified AY13416 from Senegal as its closest relative. 
Env gp41 analysis identified JO207 and JO218 as A1 and B subtypes respectively. 
HIV-1 blast identified HO540689 an A subtype from Kenya and DD153311 a subtype 
B from France as the closest associated relatives of JO207 and JO218 respectively. 
JO224 was the only sequence which could not be assigned a subtype. Hyper-
mutation was not detected in any of the sequences; sequences identified with 
frameshifts and stop codons were re-analyzed and verified (Data not shown).  
 
2.3.5 HIV-1 subtyping using online subtyping tools 
2.3.5.1 Recombinant Identification Program (RIP) 
Sequence analysis of gag, pol, accessory gene and env gene fragments identified 7 
sequences as non-subtype C or possible recombinants. A summary of RIP results 
can be found in Table 2.16.  
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Table 2.16 RIP analysis of non-subtype C sequences 
 
gag pol accessory genes env gp41 
JO162 A1/C - - C 
JO189 A1/A2/C/D/F1/F2/J C C - 
JO201 A1 A1 - - 
JO207 C - A1/G A1 
JO209 A1 G - - 
JO218 C - C B 
JO224 C C/F1/G C Not determined 
JO286 - - C/H C 
   
2.3.5.2 Rega 3.0 subtyping analysis 
The Rega 3.0 tool was used to analyses gag p24, pol, accessory and env gp41 gene 
fragments and designated sequences according to HIV-1 subtypes. A total of 52/54 
(96%) gag sequences were characterized as subtype C. However 2 sequences 
JO202 and JO247 only showed 81% and 86% support for subtype C 
characterization respectively. Two (4%) sequences were also characterized as A1 
subtypes. Pol gene analysis identified 44/47 (94%) sequences as subtype C, 1 
sequence as a HIV-1 CRF 06_CPX and 1 sequence as a K subtype, however the 
support for this subtype designation was only 38%. Accessory gene analysis JO207 
was identified as an A1 subtype with 100% support, with the remaining 45/46 (98%) 
samples subtyped as C’s. Env gp41 analysis identified 3 possible recombinants: 
JO207 (subtype J), JO218 (subtype B), and JO224 (subtype A1). The subtype 
support was however low for JO207 (33%) and JO224 (45%) while JO218 had a 
subtype support of 99%. Results of possible recombinants and non-subtype C’s 
have been summarized in Table 2.17.  
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Table 2.17: Summary of possible recombinants and non-subtype C’s identified with 
REGA 
 
gag pol accessory genes env gp41 
JO162 C - - C 
JO189 C C C - 
JO201 A1 A2 - - 
JO207 C - A1 J 
JO209 A1 06_cpx - - 
JO218 C - C B 
JO224 C K C A1 
JO286 - - C C 
 
2.3.5.3 jpHMM Analysis 
Genetic subtyping with jpHMM identified the majority of the cohort as subtype C; 
however genetic profiling also identified a number of possible recombinants in the 
patient cohort. JpHMM analysis also identified two additional sequences JO176 and 
JO213 as possible BC recombinants. The jpHMM results are summarized in Table 
2.16.  
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Table 2.16 jpHMM results of non-subtype C sequences 
 
gag pol accessory genes env gp41 
JO162 A2 - - C 
JO176 C BC - - 
JO189 C C C - 
JO201 A1 A1 - - 
JO207 C - A1/G A1 
JO209 A1 G - - 
JO213 C C BC C 
JO218 C - C B 
JO224 C - C C 
JO286 - - C C 
 
2.3.5.4 SCUEAL Analysis of the pol gene 
SCUEAL analysis identified 38/47 (81%) sequences as pure subtype C’s, 2/47 (4%) 
sequences as inter-subtypes (C/G, G/U) and 6/47 (13%) sequences as intra-subtype 
C’s. The JO201 was identified as an A1 ancestral subtype. SCUEAL results are 
summarized in Table 2.17. 
 
Inter-subtype recombinants 
SCUEAL identified JO209 as a G/U inter-subtype recombinant with a confidence 
assignment of 0.81, and support for recombination of 1. In addition JO224 could be 
identified as a C/G recombinant with confidence assignment of 0.81 and 
recombination support of 0.96. 
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Intra-subtype recombination 
Sequences JO183; JO186; JO193; JO210; JO232 and JO240 were identified with 
intra-subtype recombination with either 1 or 2 recombinant breakpoints. Confidence 
assignments for intra-subtype recombination ranged between 0.53 and 0.90 while 
support for recombination ranged between 0.74 and 0.99.  
 
 
Table 2.17 SCUEAL results of recombinants 
Name Subtype Expanded subtype 
Confidence 
in 
Assignment 
Support for 
recombination 
Support for 
intra-subtype 
recombinatio
n 
JO183 C 
C intra-subtype 
recombinant 
(2 breakpoints) 
0.903324 0.90339 0.90339 
JO186 C 
C intra-subtype 
recombinant 
(2 breakpoints) 
0.776941 0.777905 0.777905 
JO193 C 
C intra-subtype 
recombinant 
(1 breakpoints) 
0.530475 0.744084 0.744084 
JO201 A-ancestral A-ancestral 0.988561 0.000586802 0 
JO209 G,U 
recombinant 
G,U inter-subtype 
recombinant. 0.813492 1 0.000175057 
JO210 C 
C intra-subtype 
recombinant 
(1 breakpoints) 
0.656377 0.948072 0.948069 
JO224 C,G 
recombinant 
G,C inter-subtype 
recombinant. 0.815037 0.964625 0.00205636 
JO232 C 
C intra-subtype 
recombinant 
(1 breakpoints) 
0.823584 0.931891 0.93189 
JO240 C 
C intra-subtype 
recombinant 
(2 breakpoints) 
0.715358 0.991571 0.991571 
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2.3.6 Phylogenetic Analysis using MEGA version 5.1 
Phylogenetic analysis was used to investigate the relationships between cohort 
sequences and subtype reference sequences and also to confirm the results 
obtained from online subtyping tools.    
 
Construction of partial gag Neighbor-joining tree 
A neighbor joining tree (Figure 2.4) was constructed using sequences from the 
LANL database [http://www.hiv.lanl.gov]. The analysis involved 81 nucleotide 
sequences. The majority of the samples clustered with subtype C sequences: 
C.AF067155, C.AY772699, C.U46016, CU52953 (indicated in Figure 2.4B), 
however JO201 was identified as an outlier and clustered around A1 sequences: 
A1.DQ676872, A1.AB253429, A1.AB253421, and corresponded with the Rega 3.0 
and jpHMM analysis. In addition JO209 clustered with CRF06_cpx.AF064699 and 
CRF06_cpx.AY535659; however jpHMM and Rega 3.0 analysis identified this 
sequence as an A1 subtype.    
Construction of partial pol Neighbor-joining tree (Figure 2.5) 
The phylogenetic clustering observed in the gag Neighbor Joining tree was similar to 
the clustering of the pol tree. The same clustering patterns were observed with 
subtype C and the reference sequences C.AF067155, C.AY772699, C.U46016, and 
CU52953 (indicated in Figure 2.5B), as well as with JO201 and the A1 sequences: 
A1.DQ676872, A1.AB253429, A1.AB253421, and JO209 with 
CRF06_cpx.AF064699 and CRF06_cpx.AY535659 (Figure 2.5A). The similar 
clustering patterns observed in the gag and pol trees therefore verify the results 
obtained.    
Construction of Accessory gene Neighbor-joining trees (Figure 2.6) 
The accessory phylogenetic tree identified four cluster groups with the largest 
consisting of 21 query sequences and C.AY772699. Smaller clustering was 
observed between JO183, JO195, JO286 and C.U52953. JO213 was identified as 
an outlier while JO207 clustered near A1.DQ676872 and A2.AF286238. Due to the 
short DNA sequence generated for gp41 a reliable tree could not be generated.  
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Figure 2.4 Neighbor joining tree of gag gene. A Neighbor joining tree of gag 
sequences (~ 484bp) and reference sequences was constructed. Each query 
sequence is indicated with black squares. Bootstrap values of greater than 70% are 
indicated on the condensed tree (A) and uncondensed (B) portion of gag tree. 
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Figure 2.5 Neighbor joining tree of pol gene. A Neighbor joining tree of pol 
sequences (~1.2kb) and reference sequences was constructed. Each query 
sequence is indicated with black squares. Bootstrap values of greater than 70% are 
indicated on the condensed tree (A) and uncondensed (B) portion of pol tree 
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Figure 2.6 Neighbor Joining tree of accessory reference and query sequences. 
The phylogenetic tree was drawn in Mega 5v.1 with Kimura 2 parameter and 
consisted of cohort and query sequences approximately 1.3kb in length. 
Bootstrapping was performed with 500 replicates with significant values indicated on 
tree. Query sequences are indicated with colored squares. 
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2.3.7 Analysis of resistant mutations within the patient cohort 
Analyses of antiretroviral resistance were primarily based on HIV RNA extracted 
from patient plasma. The pol sequences were used for the identification of possible 
major and minor mutations in the three antiretroviral categories namely: PIs, NRTIs 
and NNRTIs. Sequences were screened for mutations using the Stanford HIV-1 drug 
resistance database as well as CPR. The CPR tool could not identify any transmitted 
resistance in any of the sequences. The Stanford HIV-1 database detected no viral 
susceptibility to antiretroviral compounds in most pol sequences. However eight 
samples: JO189, JO209, JO213, JO214, JO220, JO225, JO232 and JO233 all 
displayed low level resistance to Nelfinavir (NFV), a PI. However, most of these 
sequences contained no minor or major PI mutations or NRTI and NNRTI mutations 
with the exception of JO209.  
In addition JO209 and five other sequences: JO186, JO201, JO236, JO247, JO248 
could all be identified with either a minor PI mutation or a NNRTI mutation. JO186 
and JO201 were both identified with L10I, a minor PI mutation while JO248 was 
identified with another minor PI mutation A71T. JO209, JO236, JO247 were 
identified with the NNRTI mutations: V179E, K103R, E138A respectively.  
2.4. Discussion 
Genetic sequencing investigates the nucleotide base sequence of an organism and 
utilizes subtyping programs to characterize viral strains. However genetic 
characterization can prove difficult as a result of high genetic variability (Spira et al., 
2003). It is therefore important to utilize different programs to characterize the virus.  
In this study gag, pol, accessory gene and gp41 gene fragments were analyzed with 
subtyping programs (RIP, Rega 3.0, jpHMM and SCUEAL) to characterize the viral 
subtypes in the HAND cohort and confirmed with phylogenetic trees. In addition to 
vial subtyping pol sequences were also analyzed for possible drug resistance.  
2.4.1 Sequence Analysis of HAND cohort  
Using Rega 3.0 and jpHMM subtyping tools, we collectively identified two possible 
B/C recombinants (JO176, JO213), one A1 subtype (JO201), two A1/G 
recombinants (JO207 and JO209) and one A1/C recombinant (JO224).  
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Subtype B has been reported in parts of Asia, Brazil, India and America. However, 
the co-circulation of subtype B and C in IDU s in Brazil and Asia have resulted in two 
recombinant forms CRF07_BC and CRF08_BC. Similarly, subtype B is the dominant 
strain in Western Europe, Australia and North America; however the diversity of 
subtype B is greatest in South American countries such as Brazil and Argentina with 
the circulation of B, C, F, BC and BF recombinants (Tebit & Arts, 2011). Likewise the 
co-circulation of subtype B and subtype C in heterosexual and homosexual 
populations in South Africa could explain the BC recombinants identified in the 
HAND cohort. Conversely ambiguous results were obtained for JO176 and JO213.  
Cohort sequences were further analyzed with SCUEAL, which allowed for more in 
depth analysis of subtype classification, especially for sequences which were 
previously thought to be pure single subtypes. Apart from subtype C, subtype A1 
was the most common amongst the recombinants and was correctly detected by all 
three online sequencing tools. The number of recombinants identified initially 
expanded from the six inter-subtype recombinants to include an additional nine 
cases of intra-subtype C recombinants, drastically increasing the level of 
recombination from 9.3% to 23.43%. Interestingly, recombination occurred in 20.31% 
of HAND patients with recombinants being identified in 3 cases of ANI (4.68%), 8 
cases of MND (12.5%) and 2 cases of HAD (3.12%). It is clear that a trend towards 
more complex recombinants is emerging, but it is still unclear whether this level of 
recombination is significant to HAND patients. 
Similarly, HIV-1 subtype C was identified as the dominant strain in the HAND cohort, 
with a number of subtype C clusters observed in both gag and pol phylogenetic 
trees. This finding indicates that this subtype population within the HAND cohort did 
not originate from a single common ancestor but rather is due to the introduction of 
multiple viruses from various geographical sources. The distribution of the subtype C 
strain is not confined to sub-Saharan Africa and has established itself in a number of 
other countries. Subtype C circulates at low levels in Kenya and Uganda as either a 
pure subtype or as a recombinant strain, but with decreasing incidence. Previous 
reports state that the circulation of subtype C in China is a by-product of the 
introduction of subtype C from South Africa to India. Other studies have also 
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identified an association between the subtype C epidemic in East Africa, South 
America and the United Kingdom (UK) (Tebit & Arts, 2011; de Oliveira et al., 2010).   
2.4.2 Phylogenetic analysis of HAND cohort 
The clustering pattern observed for JO176 and JO213 was identified them as 
subtype C in both the gag and accessory phylogenetic trees. For JO213 the pol 
phylogenetic tree clustered with subtype C strains while the clustering pattern for 
JO176 suggested that it was indeed a BC recombinant. Though, due to the 
ambiguity of these samples, full genome sequencing would be necessary to fully 
elucidate the subtype of these samples.   
The gp41 and accessory genes of JO207 was characterized as an A1 recombinant 
and clustered with sequences originating from Rwanda and Australia. This clustering 
pattern is unusual and could have been introduced with immigration. The dataset 
used to characterize JO207 also included another African A1 sequence, which 
originated from Uganda. Subtype A has been a major circulating strain within 
Uganda and Kenya since the mid-1980’s, (Hu et al., 2000), with the Kenyan subtype 
A strain sharing homology with other African countries such as Uganda, South 
Africa, Ethiopia, Rwanda, Botswana and Democratic Republic of Congo (DRC). This 
may indicate direct transmission between migrants. Subtype A has also been slowly 
evolving and diverging into new strains which share homology with strains in India, 
Australia and Sweden, possibly indicating the spread of these strains from or to 
Kenya (Khoja et al., 2008). 
The sequence for patient JO209 was screened for recombination and could not be 
easily subtyped. Phylogenetic analysis identified the sample as a CRF06 with a 
mosaic genome structure consisting of subtypes A, G, J and K. This is the first 
identification of the virus in South Africa, which originates from the Congo, and 
indicates the introduction of new CRF’s into the South African population (Zhang et 
al., 2010). 
The data of this cohort was correlated with previous studies, which found subtype C 
as the dominant strain in Cape Town. However, frequent detection of recombinants 
and URF’s has made the HIV-1 epidemiology in Cape Town progressively more 
heterogeneous. According to Neogi et al, pure subtypes are steadily being replaced 
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by more complex mosaic genome structures (Neogi et al., 2011). This is evident in 
the increasing number of recombinants detected in recent years. In addition, a study 
conducted by Jacobs et al., (2008) found that a small percentage of their cohort were 
resistant to the current ART regime. Other studies have observed a similar trend in 
treatment naïve patients with 10% identified as being resistant at baseline. 
2.4.3 Analysis of Drug Resistance Mutations in Cohort 
In 2001 an ART roll out program was initiated in areas of Cape Town. By 2008 
approximately 213 000 people had been enrolled and were receiving ART on a daily 
basis. ART therapy works by suppressing HIV-1 replication through intercepting viral 
RT and PR activities (Clavel and Hance 2004). However, drug therapy and 
immunological pressures also actively selects for drug resistant viral strains. These 
strains are then archived in resting white blood cells and re-emerge once ART fails 
and can be spread within the population (Shafer et al., 2007). 
During this study HIV-1 sequences from treatment-naive patients were analyzed for 
possible resistance mutations.  Low level resistance to the PI NFV was observed in 8 
cohort samples. According to the Stanford database (http://hivdb.stanford.edu ), drug 
resistance to this inhibitor is caused by the presence of mutations such as D30N 
working in conjunction with other accessory mutations: L63P, A71V and L90M.  NFV 
resistance can also occur in the presence of T74S, a mutation which improves viral 
fitness in subtype C strains. The T74S mutations is reported to have a high natural 
mutation frequency in treatment-naïve subtype C patients of 18% (Soares et al., 
2009). Our cohort had a T74S mutation frequency of 14.06% with all 8 samples 
being identified with this mutation and had a mutation score of 15 for the NFV 
inhibitor, which according to the Stanford resistance database, is indicative of low-
level resistance. In addition the observed NFV resistance occurred in 4 patients 
(JO209, JO189, JO214 and JO220) diagnosed with MND. According to Tozzi et al., 
(2007), patients with advanced cognitive impairment have a higher risk of developing 
ART drug resistance. Even more concerning is the fact that these patients are 
treatment naïve which may pose a problem for upcoming treatment.      
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2.5. Conclusion 
This study has shown that sequences of the HAND patients are predominantly 
subtype C with at least 15 cases of possible inter-subtype and intra-subtype C 
recombinants being identified. In addition, epidemiological trends are difficult to 
predict, especially since the patterns of internal and cross-border mobility have 
changed considerably over the last three decades and may therefore contribute to 
the current epidemiological shift of HIV-1 being observed in South Africa. Continued 
evolution of subtypes and emergence of new URFs and CRFs may further 
complicate the development of effective strategies against HIV-1and therefore 
emphasizes the need for continued HIV-1 surveillance. Furthermore, the presence of 
resistance in our cohort at baseline highlights the necessity of drug resistance testing 
surveillance especially for treatment naïve patients.  
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CHAPTER THREE 
Molecular characterization of the tat gene and protein 
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3.1. Introduction 
In a recent article, Cowley et al (2010) identified a number of point mutations 
(Chapter 1, Figure 1.8) within HIV-1 Tat subtype B isolates. These mutations were 
identified within CNS and lymphoid tissue and were localized within the first exon of 
Tat. The majority of the mutations were associated with the transactivation ability of 
the tat gene. According to Cowley et al. (2010) these mutations disrupts the RNA 
stem loop structure (TAR) and reduces tat transactivation.  
 
Primarily, this chapter will focus on HIV Tat exon 1 as limited amino acid composition 
and point mutational information is available for Tat exon 2. The chapter will also 
investigate genetic conservation of full-length, cohort-derived Tat sequences and 
characterize the amino acid composition of the Tat exon 1 presented in the cohort. 
This characterization allows us to determine the homology between the cohort-
derived tat exon 1 sequences and those described by Cowley et al. (2010) found in 
the CNS; it also affords us the opportunity to determine the frequency of these amino 
acids in subtype B and subtype C sequences (obtained from the LANL database); 
and, finally, provides some insights into the amino acid signature patterns of the 
chemotactic and neurotoxic domains of Tat exon 1. A schematic overview of the 
sequence databases and software packages used to characterize the tat gene and 
protein is shown in Figure 3.1.  
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Figure 3.1 Overview of steps used to analyze HIV-1 tat genes and Tat proteins.  
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3.2. Materials and methods 
3.2.1 Software and databases used for signature pattern analysis 
All the reagents, equipment, and software applications that were used during the 
course of this study are listed in Tables 2.1 - 2.3. Registered trade mark items and 
trade mark products are indicated by the symbols ® and TM respectively. 
 
Table 3.1. List of chemicals and kits used during the study. 
Software 
packages 
References and/or licensed companies 
Geneious 5.5.7 Biomatters Ltd, Aucklandland, NZ 
SeqPublish http://www.hiv.lanl.gov/content/sequence/SeqPublish  
Los Alamos http://www.hiv.lanl.gov/components/sequence/HIV  
VESPA http://www.hiv.lanl.gov/content/sequence/VESPA  
WEBLOGOS (Computational Genomics Research Group, University of 
California, Berkley) 
 
3.2.2 HIV-1 tat sequence datasets   
Three sequences datasets were retrieved from the LANL database 
(http://www.hiv.lanl.gov/components/sequence/HIV/search/search.html) and used to 
compare the various mutations present in the first exon of the tat gene. These 
sequence datasets included: Indian subtype C (n=203), South African subtype C 
(n=195) and subtype B sequences (n=334).  
3.2.3 Nucleotide and amino acid sequence alignments 
The study cohort sequences were imported into Geneious 5.5.7 (Biomatters Ltd, 
New Zealand). Subtype C cohort sequences and the HIV-1 tat exon 1 and HIV-1 tat 
exon 2 gene fragments were extracted. Complete tat gene sequences were then 
assembled, realigned and translated into amino acid format.  
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Subtype B and Subtype C (Indian and South African) sequences datasets obtained 
from the Los Alamos Database, were aligned and the alignments were used to 
generate a consensus sequence for each dataset. The sequence alignment 
publisher tool, SeqPublish was used for this. 
(http://www.hiv.lanl.gov/content/sequence/SeqPublish/seqpublish.html). The 
interface uses a sequence alignment (nucleotides or amino acids) and identifies 
similarity between sequences with dashes. The reference sequence is either the first 
sequence in the alignment, or the software can create a consensus sequence to use 
in subsequent analyses. 
3.2.4 Signature Pattern Discovery and Recognition 
Signature pattern analysis is rapidly becoming an essential tool for genetic sequence 
analysis. The analysis software utilizes specific clusters of residues or “patterns” to 
identify proteins which are functionally similar; a task which conventional sequence 
alignment and mapping software is unable to perform (Hulo et al., 2006). Recent 
studies, focusing on the analysis of host proteins incorporated by lentiviruses, has 
highlighted the importance of amino acid characterization, emphasizing its potential 
role in better understanding HIV-1 pathogenesis and the prospects for the 
identification of new ARV therapy targets (Li et al 2012). Signature patterns between 
background sequences and query sequences were analyzed using two 
bioinformatics software packages: (1) viral epidemiology signature pattern analysis 
(VESPA) and (2) WebLogos (Computational Genomics Research Group, University 
of California, Berkley). Each tool was used to analyses specific aspects of the tat 
sequences resulting in a comprehensive overview of the observed conservation in 
cohort-derived tat proteins at a molecular level.  
VESPA  
VESPA analyzed the tat motif and point mutations in tat exon one only, as mutations 
in the second tat exon have not yet been functionally characterized. VESPA defines 
signature patterns, such as atypical amino acid or nucleotide residues, and 
calculates the frequency of each amino acid or nucleotide at each position in an 
alignment of two sequence subsets. The VESPA program identifies mutual amino 
Stellenbosch University  http://scholar.sun.ac.za
71 
 
acids, conferring altered functionality, as well as non-functional differences between 
the reference and the query sequences.  
Three types of patterns can be identified with VESPA: (1) an inflexible signature in 
which uncommon residues in the background sequence are also present in query 
sequences, (2) dominant residue signatures in which the more common residues in 
the query sequences differ from that seen in the reference sequence, (3) direct 
signatures in which a consensus is generated and used to reflect the predominant 
amino acid at each position (Korber and Myers, 1992).  
WebLogos   
WebLogos exclusively interrogated the neurotoxic and chemotactic domains of Tat, 
spanning amino acids 24–51 and 31–61 respectively. Characteristically, Tat displays 
a great neurotoxin and chemotactic affinity. Any amino acid substitutions in this 
domain are likely to affects both mechanisms.  
Sequences WebLogos are graphical representations depicting the prevalence of an 
amino acid or nucleic acid multiple sequence alignment. The logos are comprised of 
stacks of characters with every stack representing a single nucleic or proteomic loci 
interrogated. Sequence conservation is indicated by the overall height of the 
character, while the height of characters within the stack indicates their relative 
frequency at that position. A sequence logo provides a more descriptive 
representation of the patterns within a multiple sequence alignments and can rapidly 
reveal significant features of the alignment, which would normally be difficult to 
recognize.  
3.3. Results 
3.3.1 Generation of Datasets 
The subtype B sequence dataset was the largest amongst the three datasets and 
included sequences from a total of 33 European, African and Asian countries. Full 
length tat subtype B (n=332) and South African subtype C sequences (n=179) could 
be retrieved for comparison to the study cohort. A limited amount of full length tat 
Indian subtype C sequences (n=7) could be retrieved from the Los Alamos database. 
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As a result additional Indian subtype C sequences were analyzed, which consisted 
only of Tat exon 1 sequences (n=203). Sequence datasets are summarized in Table 
3.1 (the complete list of sequences used for this analysis has been described in the 
Appendix). The 3 different sequence datasets were compared to full length tat 
sequences from the patient cohort (n=34). 
Table  3.1 Characterization of HIV-1 sequence datasets 
Tat subtype B and subtype C sequence datasets 
Code Name of country Number 
of taxa Code Name of country 
Number 
of taxa 
AR Argentina 9 HT Haiti 4 
AU Australia 29 IN India – subtype C 210 
BO Bolivia 1 IT Italy 1 
BR Brazil 18 JM Jamaica 1 
CA Canada 6 JP Japan 15 
CN China 4 KR Korea, Republic of (South) 4 
CO Colombia 4 MM Myanmar 1 
CU Cuba 2 NL Netherlands 1 
CY Cyprus 32 RU Russian Federation 3 
DE Germany 1 TH Thailand 3 
DK Denmark 13 TT Trinidad and Tobago 4 
DO Dominican republic 2 TW Taiwan, Province of China 1 
EC Ecuador 2 UA Ukraine 3 
ES Spain 7 US United States of America 147 
FR France 1 UY Uruguay 2 
GA Gabon 1 YE Yemen 2 
GB United Kingdom 3 ZA South Africa – subtype C 179 
GE Georgia 2 TOTAL 721 HK Hong Kong 1 
 
3.3.2 Sequence alignments 
A consensus subtype C sequence was generated from the study cohort and aligned 
to the cohort sequences in Figure 3.2 to determine the level of amino acid variability 
in HIV-1 tat. The alignment focuses on the various domains of tat and indicates the 
level of variability across these five domains. The observed point mutations showed 
clustering in the cys-rich domain, basic domain and parts of the C-terminal domains. 
Bioinformatics was utilized to investigate the landscape of the tat gene and to obtain 
comparative data regarding the genetic and amino acid variation in the HAND 
cohort. VESPA and WebLogos were utilized to identify areas of conservation and 
hotspots of variability in tat. .  
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A number of sequence specific amino acids could be identified in the HAND cohort 
with the greatest number of polymorphisms being observed in the cysteine rich, 
glutamine-rich and C-terminal domains (Figure 3.2). Furthermore mutations were 
also observed in the overlapping areas of the chemotactic and neurotoxic domains of 
Tat. The sequences JO193 and JO204 were identified with the least amount of 
variability but harbored mutations at H29K, A58T, P68L, D80N, P81S and K19Q, 
K24T, H29K, P81Q, E96K respectively. Furthermore, the sequences labeled: JO168, 
JO218 and JO235 presented with premature stop codons with JO168 and JO218 
containing stop codons at F100* and JO235 at position S86*. It has been shown that 
premature stop codons lead to truncated protein forms which are often inadequate 
for proper cell functioning (Jeang et al., 1999). Although, observed stop codons 
occurred in the C-terminal domain and may therefore still possess normal 
functioning, albeit reduced.  
Sequence analysis also identified 16 sequences with mutations at sites which have 
previously been characterized as functionally important for Tat transactivation and 
post translation modifications such as phosphorylation (Cowley et al. 2010). 
Mutations associated with transactivation occurred at E2D, C31S/A while mutations 
associated with phosphorylation was identified at S46Y, S57R, S62G and D64N/G. 
An unexpected C31A mutation was identified in the dicysteine motif of Tat which has 
previously not been identified in subtype B sequences. Furthermore, JO207 was 
identified with the highest level of variability with a total of 26 mutations, 3 of which 
were located in sites associated with transactivation and phosphorylation. The 
identification of amino acid changes in functionally important sites reflected the 
heterogeneity of Tat sequences. Therefore to assess the relative frequency of these 
mutations an examination of clade B and clade C sequences were performed with 
VESPA. 
3.3.3. Signature pattern analysis of amino acid residues  
Sequence WebLogos and VESPA analysis was performed on subtype B and 
subtype C sequences to identify point mutations in sixteen functionally important 
sites of Tat. Table 3. 2 summarize the frequency of conserved amino acids as well 
as its amino acid substitutions. In addition, the chemotactic and neurotoxic domains 
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of Tat were analyzed for signature patterns and presented with sequence WebLogo 
in Figure 3.3.  
The conservation of amino acids in 13 of the 16 sites was above 80% while the 
remaining 3: C31S, 57S, and 64D had frequency levels of 50.65%, 46.21% and 53% 
respectively. Observed amino acid substitutions could be characterized into 1 of 6 
categories: Mutations shared amongst all sequence subsets and the cohort, 
mutations unique to subtype B, mutations unique to subtype C India, mutations 
unique to subtype C South Africa, mutations shared by subtype B and subtype C and 
mutations shared between subtype C sequences. Subtype specific mutations were 
most prevalent in subtype B sequences (22), which were closely followed by South 
African subtype C sequences (21) and finally subtype C Indian sequences. The 
frequencies of these subtype specific mutations were between 0.13% and 0.91%. 
Mutations shared amongst sequences yielded similar frequencies except in 
positions: E2D, C31S/A/T/N/G, S57R and D64T with mutations frequencies between 
15.27% and 48.56%.  
Position 31 was of particular interest as mutations here have been implicated in the 
apoptotic ability of HIV-1 Tat and the progression of HAND. The patient cohort 
showed similarity to both the subtype B and subtype C strains as it contained both 
cysteine and serine residues in position 31. Mutation frequencies were as follows: 
C31S (50.65%), C31C (48.30), C31A (0.52%), C31T (0.26%), C31N (0.13%) and 
C31G (0.13%). Interestingly the novel C31A mutation identified in the HAND cohort 
could only be identified in South African subtype C sequences. Sequence WebLogos 
identified 3 amino acid sequences which were relatively conserved amongst 
sequence subsets: 25CYCK28, 36VCF38 and 41KGLGISYGRKKRRQRR56 with 
variability occurring at positions 24, 26, 29, 31, 32, 36, 40, 41 and 57-61. The amino 
acids Asn, Thr, and Lys were found at position 24 amongst all sequences subsets as 
well as Pro in Subtype B sequences. Tyr and Phe were recognized at positions 29 
however, the latter displayed a greater level of conservation in all four sequences 
than Tyr. 
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Figure 3.2: Nucleotide sequence alignment of subtype C consensus sequence and 34 full length tat sequences. 
N-terminal, cysteine-rich, core, basic and C-terminal domains are indicated, with blue and red boxed areas representing 
chemotactic and neurotoxic domains respectively. Dashed areas indicate areas of similarity.  
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Table 3.2: Frequency of mutations in functionally important Tat protein sites used for 
transactivation and phosphorylation. Purple = Indian subtype C specific mutations, Green = South African 
subtype C specific mutations, Pink = subtype B specific mutations, Red = mutations identified in subtype C, subtype 
B and cohort sequences, Orange = mutations identified in subtype B and subtype C sequences (India and South 
Africa), Turquoise = subtype C specific mutations, Yellow = subtype B and South Africa subtype B specific 
mutations. 
Amino Acid 
position Consensus
a.a E D G K P R
n 695 117 7 2 1 1
% 90.73 15.27 0.91 0.26 0.13 0.13
a.a W * S G
n 762 2 1 1
% 99.47 0.26 0.13 0.13
a.a S N C
n 764 1 1
% 99.73 0.13 0.13
a.a C R S W A V
n 758 4 1 1 1 1
% 98.95 0.52 0.13 0.13 0.13 0.13
a.a K N R Q
n 761 3 1 1
% 99.34 0.39 0.13 0.13
a.a S C A T N G
n 388 370 4 2 1 1
% 50.65 48.3 0.52 0.26 0.13 0.13
a.a C G W V R A
n 757 3 2 2 1 1
% 98.82 0.39 0.26 0.26 0.13 0.13
a.a K Q N S
n 762 1 2 1
% 99.47 0.13 0.26 0.13
a.a S Y F P C K I V
n 707 34 11 5 4 1 1 1
% 92.29 4.43 1.43 0.65 0.52 0.13 0.13 0.13
a.a Y H N M G F *
n 738 15 7 3 1 1 1
% 96.34 9.79 0.91 0.39 0.13 0.13 0.13
a.a K R I
n 762 3 1
% 99.47 0.39 0.13
a.a K S R N E F
n 758 2 2 1 1 1
% 98.95 0.26 0.26 0.13 0.13 0.13
a.a R S Q E A P K
n 747 35 11 3 1 1 1
% 97.51 4.56 1.43 0.39 0.13 0.13 0.13
a.a S R G T N A K * P
n 354 372 13 9 8 5 2 1 1
% 46.21 48.56 1.69 1.17 1.04 0.65 0.26 0.13 0.13
a.a S N G R C H D T V Y E Q
n 658 39 28 15 7 6 4 3 3 1 1 1
% 85.9 5.09 3.65 9.79 0.91 0.78 0.52 0.39 0.39 0.13 0.13 0.13
a.a D T N A G I K P Q S H V E
n 406 232 45 21 18 17 5 4 2 2 2 2 1
% 53 30.28 5.87 2.74 2.34 2.21 0.65 0.52 0.26 0.26 0.26 0.26 0.13
62
64
47
50
51
56
57
28
31
34
41
46
Polymorphism and relevant frequency
2
11
16
22
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Figure 3.3: Chemotactic and neurotoxic regions of HIV-1 Tat. (A) Subtype B, (B) India Subtype C, (C) South African Subtype C, and (D) cohort 
sequences. The x-axis indicates the position of amino acid, y-axis indicates the frequency of amino acid. The sequence logo was developed at 
http://weblogo.berkeley.edu/logo.c
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3.4. Discussion  
The HIV-1 genome is a hive of constant change and is incessantly subjected to 
evolution in the form of mutations which are possibly damaging to viral fitness and 
replication. However the error prone nature of HIV has resulted in a multitude of 
diverse strains which are not only functional but capable of successfully infecting and 
replicating in various host cells (Evans et al., 2009). Subtype C viruses predominates 
in countries such as India and South Africa and are genetically distinct from other 
subtypes such as HIV-1 B (Ranga et al., 2004). Though, little is known about the 
genetic differences between HIV tat subtype B and subtype C. This chapter sought 
to identify amino acid differences in Tat, between the viral subtypes B and C. A total 
of 732 subtype B and subtype C sequences were retrieved from the Los Alamos 
sequence database. Sequences were analyzed using bioinformatics to identify 
amino acid which were subtype specific or commonly shared amongst subtypes.   
3.4.1 Variability in functionally important amino acid positions  
Analysis of Tat amino acids revealed a high level of heterogeneity in both subtype B 
and subtype C sequences. The significant variation in Tat amino acids was 
associated with transactivation and phosphorylation. A number of the mutations 
observed were in agreement with those described (Cowley et al., 2010) with 
frequency levels of between 80% and 99%. However the sequences did vary greatly 
in positions, 31, 57 and 64. Cowley identified the mutations as C31R, R57G/K, 
T64N/D, while in our cohort and the majority of sequences analyzed, the mutations 
were identified as C31S/A/T/N/G, S57G/T/N/A/K/*/P, D64T/N/A/G/I/K/P/Q/S/H/V/E. 
Although the level of variability observed in mutations were much greater than those 
described by Cowley the mutation frequency was often below 1%.  The observed 
variability could exist as a result of HIV-1’s erroneous nature, HAART selective 
pressure or natural selection of subtype C for a more advantageous life cycle.  
3.4.2 The Dicysteine Motif 
While 99% of non-subtype C viruses can be identified as having a cysteine at 
position 31, about 4.5% of subtype C sequences in the database encoded for it. The 
cysteine rich domain of Tat is said to govern the transactivation domain of Tat and 
contains 7 conserved cysteine, mutations in this area would therefore be detrimental 
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for HIV-1 transactivation and replication. The study cohort sequences contained no 
mutations in the 7 conserved cysteine positions, except for position 31. According to 
(Ranga et al., 2004), the cysteine in position 31 is irrelevant for transactivation in 
subtype C, but is conserved in non-subtype C’s for monocyte chemotactic function, 
an activity absent in subtype C.  
Studies conducted by Mishra et al., 2004 provided evidence that the C30S31 
mutation in subtype C decreased chemotactic function without affecting 
transactivation. Furthermore, the study also showed that the C30S31 mutation was 
conserved among subtype C sequences regardless of geographic distribution. 
Conservation of the C30S31 mutation was observed in the analysis of the study 
cohort as well as subtype C Indian and South African sequences retrieved from the 
Los Alamos database. Ranga et al (2004) has suggested that the conservation of 
serine in position 31 amongst subtype C sequences could possibly be functionally 
advantageous to the subtype, but is yet to be described. Furthermore a study 
showed that serine residues in subtype C were phosphorylated by a cyclin 
dependent kinase-2 mechanism (Tiwari et al., 2012) which is important for HIV-1 
transcription and the activation of integrated HIV-1 provirus which further supports 
Ranga’s claim that the C30S31 mutation could be beneficial to subtype C and is a 
possible phosphorylation site which supplements the loss of a cysteine and its trans-
activation activity.  
In addition, protein studies conducted by Mishra et al., 2008 identified subtype B 
proteins with C30C31 mutations with a higher order of flexibility than the isogenic 
form containing the C30S31 mutation. It was suggested that the higher order of 
flexibility in subtype B could result in the higher level of activity reported for subtype 
B. This could possibly explain the high conservation of cysteine residues in position 
31, observed in the subtype B sequences analyzed in this study. Despite the error 
prone nature of HIV-1 replication, and the variability observed, Tat still retains its 
complex functions of gene expression and replication. It has been reported that short 
conserved amino acid sequences associated with Tat functioning are utilized for this 
function (Dey et al., 2012).  
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3.4.3 The chemotactic and neurotoxic domains of Tat 
Findings from the sequence alignments prompted further investigations of the patient 
cohort.  WebLogo software provided a detailed and more precise description of 
sequences, therefore four weblogo’s was constructed, one for each sequence subset 
and one for the patient cohort which specifically looked at the chemotactic and 
neurotoxic domains of HIV-1 tat. The patient cohort showed similarity to both the 
subtype B and subtype C strains as it contained both cysteine and serine residues in 
position 31. The implications of this observations is not clear, but may be elucidated 
with further functional studies. Positions 24-51 and 31-61 are responsible for the 
chemotactic and neurotoxic properties of Tat respectively (Mishra et al., 2008).  
Mutations in this area would therefore most likely result in the augmentation of any 
biological activity. Single amino acid polymorphisms could be observed throughout 
the chemotactic and neurotoxic domains, although, sequence WebLogos also 
identified short amino acid sequences which were conserved. Tat is a strong chemo-
attractant for macrophages, monocytes and dendritic cells. Amino acid residues in 
the cysteine rich domain, a conserved Ile39 and a SYXR motif at position 46–49 of 
Tat are all critical for chemokine receptor binding and signal transduction. 
3.5. Conclusion 
Comparison of subtype B, subtype C (Indian and South African) and the study cohort 
sequences revealed a high level of variation in amino acid residues. The frequency 
of point mutations in the subtype B strains was slightly higher than those identified in 
the subtype C strains. The implications of these novel mutations on the 
transactivation of tat remains unclear, therefore further analysis is necessary. The 
use of signature pattern analysis goes beyond simple nucleotide or amino acid 
distance relationships and could be useful for molecular epidemiologic investigations 
of HIV transmission, especially linked transmissions and questions of dual infection.  
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CHAPTER FOUR 
Functional analysis of the tat gene and protein 
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4.1. Introduction 
As discussed in previous chapters a high level of variability as well as areas of 
conservation was observed throughout the tat protein in the study cohort. When 
compared to subtype B and subtype C sequences, cohort sequences showed 
similarity to both. Signature pattern analysis identified amino acid residues which 
were clade specific with more variation occurring in subtype B than subtype C. 
However a total of 171 amino acids were identified as mutually occurring amongst all 
sequence subsets and the HAND cohort. Among these was the amino acids 
identified in the dicysteine tat motif, which was predominantly C30C31 or C30S31, 
with a small percentage of subtype B and subtype C sequences having variations 
thereof. According to Ranga et al (2004) the C30S31 mutation renders HIV-1 
subtype C defective for monocyte chemotaxis in vitro. It has also been reported that 
subtype C is characterized by lower transactivation, lower levels of induced 
apoptosis and ultimately a lower incidence of HAND (Roa et al., 2009). 
Study cohort sequences were identified with a 29% frequency of the C30C31 
mutation and a 68% frequency of the C30S31 mutation. In addition a novel mutation, 
C30A31, was identified in the cohort with a frequency of 3%. In view of the 
association between the dicysteine motif and HAND, these mutations were selected 
to investigate the biological function of tat in cell culture in vitro. Briefly, Tat genes 
containing the above mentioned mutations were constructed and cloned into 
mammalian expression vectors which were transfected into 293T cells. This chapter 
will discuss the construction of tat genes and investigate the level of apoptosis being 
induced by each mutation. An outline of the experiments used to construct and 
express tat genes in cell culture is indicated in Figure 4.1. Briefly, patient sample 
JO206 was used to construct an optimized subtype C clone and 3 tat genes 
containing mutations identified in the dicysteine motif: C30C31, C30S31, and 
C30A31. The genes were transformed into bacterial cells and cloned into CMV 
expression vectors and transfected into 293T cells. Apoptosis levels were visualized 
and quantified with flow cytometry. The experimental procedures outlined in Figure 
4.1 will be discussed in more detail in the materials and methods sections. 
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Figure 4.1 Overview of steps used to construct and express tat genes. 
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4.2. Materials and methods 
4.2.1 Construction of tat mini-genes 
Sequencing data was used to characterize the tat 1 and tat 2 genes of the study 
cohort as well as identify possible mutations present in the first tat exon. Two 
samples, JO206 and JO224 were identified as subtype C strains with the tat C30S31 
polymorphism. These samples were closely associated to the consensus sequences 
of HIV-1 tat retrieved from the Los Alamos database (LANL HIV Database) however, 
JO206 was the only sample amplifiable for both the HIV-1 tat genes and it was 
therefore chosen as a template for the construction of the HIV-1 tat genes.   
Four genes were constructed with the following polymorphisms in the tat motif: 
C30C31 (Subtype B wild-type mutation), C30S31 (Subtype C wild-type mutation) 
and C30A31 a novel mutation identified within the study cohort. An additional tat 
gene contained the subtype C wild-type mutation, however this gene had been 
codon optimized for expression in mammalian cells and would serve as a control. 
Each tat gene consisted of the complete tat 1 and tat 2 genes, start and stop codons 
for in frame expression of the tat protein, and restriction enzyme sites Pme1 and 
Sigel for easy digestion and ligation into acceptor and donor vectors. Physical 
construction of the genes was performed by Integrated DNA Technologies (IDT) who 
also verified the ligation of tat gene into the pIDT-SMART-Amp vector with DNA 
sequencing. 
4.2.2 Cloning of HIV-1 tat genes into pF4A cmvd1 flexi vector 
Transformation of tat genes into JM109 cells 
Tat genes were obtained from IDT at a concentration of 2µg/µl. The pIDT-SMART-
Amp vectors were reconstituted in 10µl of nuclease free water to a working 
concentration of 200ng/µl. In order to maximize gene yield and plasmid volume a 
bacterial transformation was performed. Each reaction consisted of 50µl of 
competent JM109 cells; 200ng/µl of tat genes was added to the tubes containing the 
JM109 cells. Reactions were then allowed to incubate on ice for 20 minutes. 
Thereafter, reactions were transferred to a water bath at 42ºC and heat-shocked for 
52 seconds. Reactions were incubated on ice for 2 minutes before adding 450µl of 
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SOC medium. Reactions were transferred to a shaking incubator for 90 minutes at 
37ºC. Transformed cells were streaked in duplicate onto LB agar plates containing 
100mg/ml ampicillin. Plates were inverted and incubated overnight at 37ºC. The 
pIDT–SMART-Amp vector contains the ampicillin resistance gene and makes colony 
selection possible. Colonies were picked and inoculated into LB broth containing 
ampicillin at a concentration of 100 mg/ml and incubated at 37ºC overnight. Plasmid 
DNA was isolated using the Pure yield midi prep kit (Promega, USA) according to 
manufacture specifications. 
Digestion and ligation of mini-genes and pF4A cmvd1 flexi® vector 
pF4A cmvd1 flexi® vector (Promega, USA) served as the first expression vector 
used to clone tat genes. pF4A cmvd1 flexi® vector is a mammalian expression 
vector constructed with cmv for both stable and transient gene expression of intrinsic 
proteins. Digestion of acceptor vector and pIDT–SMART-Amp vector plasmid DNA 
was performed concurrently using the restriction enzymes Sgf I and Pme I in 5X 
flexi® digest buffer and nuclease-free water. Both reactions were assembled 
according to the manufacturer’s specifications and digested for 30 minutes at 37°C. 
The flexi® vector reaction was further heated to 65°C for 20 minutes to inactivate the 
restriction enzymes. Membrane binding solution (20µl) was added to the reaction 
containing the digested tat gene. Reactions were stored on ice. DNA concentrations 
of each reaction were determined using the nanodropTM ND-1000 system 
(Nanodrop Technologies Inc, USA). In a 0.2ml tube, 5µl of the pF4A cmvd1 flexi® 
vector acceptor vector (50ng) was mixed with 100ng tat gene DNA. To this 1µl 
(20U/µl) of T4 DNA ligase (Promega, USA) and 10µl of 2X flexi ligase buffer 
(Promega, USA) were added. The final volume of the reaction was brought to 20µl 
by adding nuclease-free water (Promega, USA) to the reaction and incubated at 
room temperature for 1 hour. 
Transformation and bacterial culturing of recombinants  
The pF4A cmvd1 flexi® vector also contains an ampicillin resistance gene which 
facilitates colony selection in E. coli grown on LB agar containing ampicillin. High-
efficiency JM109 competent cells (Promega, USA) were thawed on ice and gently 
mixed before 50µl of the cells was transferred into a 14ml polypropylene round-
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bottom tubes (Becton Dickinson, USA) containing 2µl ligated DNA. Tubes were 
incubated on ice for 20 minutes then heat-shocked for 45-50 seconds in Haake L 
water bath with Haake D1 heating circulator (LabX, USA) at 42°C. Tubes were 
immediately returned to ice for 2 minutes and 450µl of room-temperature SOC 
Medium (Sigma, USA) was added to each tube. Tubes were incubated for 1.5 hours 
at 37°C with shaking (150 rpm).  Each transformation (50-100µl) was plated onto 
duplicate plates containing 100µg/ml ampicillin and incubated overnight at 37°C. 
After 24 hours, colonies were picked and inoculated into 250ml LB broth containing 
ampicillin at a concentration of 100 mg/ml and incubated at 37ºC overnight.  
Bacterial cell cultures were grown for approximately 16 hours and purified using the 
Pure-Yield Plasmid Midi-prep System from Promega (Promega, USA). Bacterial cell 
suspension was centrifuged at 5000 X g for 10 minutes. The supernatant was 
discarded and replaced with 6ml of cell re-suspension solution and inverted 3-5 
times. Cells were incubated for 3 minutes at room temperature before adding 6ml of 
cell lysis solution and inverting 5-10 times. Solution was inactivated by 10ml 
neutralization solution inverted 5-10 times and centrifuging at 15000 X g for 15 
minutes. The cleared lysate was decanted into a PureYield Clearing Column and the 
filtered DNA bound to the PureYield Binding Column. The binding column was 
washed once with 5ml of endotoxin solution and 20ml column wash solution. The 
membrane was dried by applying a vacuum for 1 minute, purified DNA was eluted in 
400µl of nuclease free water. Plasmid DNA concentrations was determined with the 
Nanodrop TM ND-1000 system.  
4.2.3 Cloning of HIV-1 tat genes into pFN22K cmvd1 flexi vector 
Digestion and ligation of cmvd1 flexi vectors  
pFN22K cmvd1 flexi® vector (Promega, USA) was used as the second expression 
vector for cloning of the tat genes. The 5X flexi® digest buffer, pFN22K cmvd1 flexi® 
vector and nuclease-free water were thawed and stored on ice. The reaction was 
assembled according to manufacturer’s specifications with 100ng of both pF4A and 
pFN22K cmvd1 flexi vector DNA digested with restriction enzymes Sgf I and Pme I 
for 30 minutes at 37°C. The final volume of the reaction was brought to 20µl by 
adding nuclease free water (Promega, USA) to the reaction.  The reaction was 
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further heated to 65°C for 20 minutes to inactivate the restriction enzymes and 
stored on ice until ligated. In a 0.2ml tube 10µl of the digested pFN22K and pF4A 
cmvd1 flexi® vector mix (100ng) was pipetted along with 10µl of 2X Flexi Ligase 
Buffer and 1µl of T4 DNA ligase (20U/µl). Nuclease free water was added to the 
reaction for a final volume of 21µl. The reaction was incubated at room temperature 
for 1 hour.  
Transformation and culturing of pFN22K cmvd1 flexi vector with tat gene 
High-efficiency JM109 competent cells (Promega, USA) were thawed on ice and 
gently mixed before 50µl of the cells was transferred into a 14ml polypropylene 
round-bottom tubes (Becton Dickinson, USA) containing 2µl ligated DNA. Tubes 
were incubated on ice for 20 minutes then heat-shocked for 45-50 seconds in Haake 
L water bath with Haake D1 heating circulator (LabX, USA) at 42°C. Tubes were 
immediately returned to ice for 2 minutes and 450µl of room-temperature SOC 
medium (Sigma, USA) was added to each tube. Tubes were incubated for 1.5 hours 
at 37°C with shaking (150 rpm).  Each transformation (50-100µl) was plated onto 
duplicate plates containing 25 mg/ml kanamycin and incubated overnight at 37°C. 
After 24 hours, colonies were picked and inoculated into 250ml LB broth containing 
kanamycin  at a concentration of 25 mg/ml and incubated at 37ºC overnight. The 
PFN22K cmvd1 flexi® vector contains a kanamycin resistance gene which facilitates 
colony selection in E. coli grown on LB agar containing kanamycin. 
Bacterial cell cultures were grown for approximately 16 hours. Plasmid DNA was 
then isolated and purified using the Pure-Yield Plasmid Midi-prep System from 
Promega (Promega, USA). Bacterial cell suspension was centrifuged at 5000 X g for 
10 minutes. The supernatant was discarded and replaced with 6ml of cell re-
suspension solution and inverted 3-5 times. Cells were incubated for 3 minutes at 
room temperature before adding 6ml of cell lysis solution and inverting 5-10 times. 
Solution was inactivated by 10ml neutralization solution inverted 5-10 times and 
centrifuging at 15000 X g for 15 minutes. The cleared lysate was decanted into a 
PureYield Clearing Column and the filtered DNA bound to the PureYield Binding 
Column. The binding column was washed once with 5ml of endotoxin solution and 
20ml Column Wash solution. The membrane was dried by applying a vacuum for 1 
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minute, purified DNA was eluted in 400µl of nuclease free water. Plasmid DNA 
concentrations was determined with the Nanodrop TM ND-1000 system.  
Screening of colonies for tat inserts 
Tat gene inserts in both the pFA4A and pFN22K CMVd1 Flexi® Vectors were 
verified with colony PCR using the primers Tat F 5´-
AGAGAAGAAAGCTTAATGGAGCCAGTAGATC-3΄ and Tat R 5´-
ACTTACAATTGTGATATAAGATTTTGATG-3΄. Reagent concentrations and cycle 
parameters have been represented in Tables 4.1 and 4.2.  Reactions were 
inoculated with colonies also inoculated in LB broth for overnight cultures The 
GeneAmp® 9700 PCR system (Applied Biosystems, USA) was utilized for 
amplification of inserts with cycle parameters described in Table 4.2. The initial 
denaturing step lyses bacterial cell walls and releases plasmid DNA which could now 
be amplified and visualized with ethidium bromide and gel electrophoresis. 
 
Table 4.1 Mastermix composition of colony PCR 
Reagent Final Concentration Volume µl 
dNTPs (10mM each) 0.2mM 1 
Tat F Primer  (40pmol/µl) 0.8pmol/µl 1 
Tat R Primer (40pmol/µl) 0.8pmol/µl 1 
25 mM MgCl2 1.5mM 3 
5X GoTaq Flexi buffer 1X 10 
5U/µl Taq DNA 
polymerase 
1.1U/µl 0.75 
Water - 32.25 
Total volume 50µl 50µl 
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Table 4.2 Cycle parameters of colony PCR 
 Temperature Time Cycles 
Initial Denaturation 94 ºC 2 minutes 1 X 
Denaturation 94 ºC 30 seconds 
40 X Annealing 55 ºC 30 seconds 
Primer extension 68 ºC 3 minutes 
Final extension 68 ºC 10 minutes 1X 
Hold 4 ºC ∞ 
 
4.2.4 Cell culture  
Cell line 
HEK 293 cells, an adherent cell line, were provided by Dr Craig Kinnear from the 
Genetics Department of Stellenbosch University and were used to investigate the 
apoptotic effects of constructed mini-genes in cell culture. HEK 293 cells are 
commonly referred to as 293T cells and are derived from human embryonic kidney 
cells. This cell line has been described as being highly transfectable and supports 
elevated levels of protein expression. 
Maintenance of Cell line 
The 293T cell line was cultured in a LabotecTM Biological Safety Cabinet Class II 
(Labotec, Germany) to protect the cell line from contamination. Cells were removed 
from liquid nitrogen and thawed with 10ml of DMEM (Lonza, Switzerland)  
supplemented with 10% foetal bovine serum (FBS) (Lonza, Switzerland) and 
0.1mg/ml streptomycin (Lonza, Switzerland). Cells were centrifuged twice at 150 X g 
for 5 minutes to remove all DMSO from cell suspension. Cells were seeded into 
25cm2 Cell Culture Flasks (Corning, USA) and incubated at 37ºC supplemented with 
5% CO2 in NUAIRETM US Autoflow CO2 Water-Jacketed Incubator (Nuaire, USA). 
After 48 hours culture media was replaced with fresh DMEM media. 
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Regular sub-culturing was performed to maintain the growth of the cell line. Once 
cells had reached 80% confluence they would be sub-cultured into new culture 
flasks. Old culture medium would be discarded and cells would be washed with 10ml 
of 1 XPBS (Lonza, Switzerland) to remove excess FBS from culture flask which may 
inhibit the effects of trypsin. Trypsin /versene (Trypsin/EDTA), a combined 
reagent (Lonza, Switzerland) (1.5ml) was added to the monolayer and gently shaken 
remove cells from the culture vessel surface into suspension solution. Cells were re-
suspended in 5ml of culture medium and transferred to a sterile 15ml High-Clarity 
Polypropylene Conical Tube (Becton-Dickenson, USA). Cell suspension was 
centrifuged at 171 X g for 5 minutes. A second wash step was performed to ensure 
removal of trypsin. Cell pellet was re-suspended in 5ml culture medium. 
In order to determine the correct seeding density for sub-culturing, the viable and 
total cell count was determined. Cell suspension was vortexed for even distribution; 
50µl of the cell suspension was removed and mixed with an equal volume of 0.4% 
trypan blue stain (Invitrogen, USA). Ten microliters of the mixture was transferred to 
a Neubauer Improved Bright-Line (Marienfeld Superior, Germany) cell counter. 
Healthy (unstained) and dead/dying (stained) cells were counted using an Eclipse 
E200 Microscope (Nikon, USA). The cell count together with the formula below was 
used to determine the percentage viable cells per millilitre. Total cells counted / 
number of squares × 104 × dilution factor = Number of viable cells/ml. Cells were 
diluted with complete DMEM to obtain a cell concentration of 1X106cells/ml and 
seeded into a new 75 cm2 cell culture flasks (Corning, USA) containing 20 ml of 
complete DMEM medium.  Cells were then incubated in a NuaireTM US Autoflow CO2 
water-jacketed incubator (Nuaire, Minnesota, USA). A second cell concentration of 
1X106cells/ml was used for the storage of excess 293T cells.  
Mycoplasma screening  
Cultured cell lines are repeatedly passaged and can therefore be easily 
contaminated by mycoplasma. Mycoplasma contamination is a major problem in 
biological research and can alter the metabolism of cells and ultimately influence the 
outcome of generated data. Cells were therefore screened for mycoplasma 
contamination using RIDASCREEN® Mycoplasma IFA (R-Biopharm AG, Darmstadt, 
Germany). A total of 25 000 cells were seeded into trac bottles containing a coated 
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glass microscope slide and 2ml culture medium and incubated for two days. Trac 
bottles were rinsed with 1X PBS and cells fixed with cold acetone for 5 minutes. The 
coated glass microscope slide was removed and attached to a glass slide with glue; 
the sample was then air-dried at room temperature. One drop of the anti-
mycoplasma-conjugate was added to the fixed cells and incubated for 20 minutes. 
After the incubation the slide was rinsed with phosphate buffered saline and washed 
twice for a total of 2 minutes in a bath of 1XPBS. The slides were incubated at room 
temperature to dry. One drop of anti-mycoplasma-conjugate was added to the center 
of the slide and incubated for another 20 minutes. After the incubation the wash step 
was repeated and the slide was air-dried at room temperature. One drop of mounting 
fluid was added in the center of each well and a coverslip was placed on it. The 
slides were observed with the Olympus BX60 fluorescent microscope (Wirsam 
Scientific, RSA) and screened for the presence of green fluorescent inclusion bodies 
within cells. 
4.2.5 Transfection and optimization of apoptosis assay 
Transfection control   
In order to ensure that the detected level of apoptosis in cell culture was a result of 
the mini-genes only, a transfection control (pFN22K CMVd1 Flexi® Vector) was used 
which had been digested with Flexi® Enzyme Blend (Sgf I and Pme I) (Promega, 
USA) to remove the barnase gene.  Since the vector cannot ligate upon itself, 
oligonucleotides, Flexi-strand-F: 5´-CGCGTAAGGGTAGGTTT-3΄ and Flexi-strand-
R: 5´-AAACCTACCCTTACGCGAT-3΄ were incorporated into the vector. The vector 
was then transformed into JM109 competent cells as described by Dr Bizahn 
Romani (PhD thesis, Stellenbosch University, 2011). Tat Clones and transfection 
control were transfected using the Extreme gene 9 transfection reagent (Roche, 
USA) according to manufacturer specifications in a 3:1 ration of 3µl of transfection 
reagent and 1µg/µl Tat clone DNA.   
Apoptosis optimization 
Flow cytometry was used to assess the apoptosis-inducing efficacy of the 
constructed tat mini-genes in cell culture. Intrinsic and extrinsic stimuli can induce 
cell death. During apoptosis, cells can be in one of three stages of cell death: early 
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apoptosis, late apoptosis or necrosis. Flow cytometry parameters for the detection of 
Annexin V-FITC (BD Biosciences, USA) and 7-AAD (Sigma, USA) fluorescent dyes 
were optimized to identify 293T cells undergoing cell death. Furthermore the use of 
FITC with 7-AAD excludes any spectral overlap and concerns regarding color 
compensation as they are detected in channels 1 and  3 of the FACS Calibur (BD, 
USA). Annexin V is a phospholipid-binding protein with a high affinity for 
phospholipid phosphatidylserine (PS). During early apoptosis the PS molecule 
translocates from the inner to the outer leaflet of the plasma membrane, thereby 
exposing PS to annexin V FITC. During late phase apoptosis the PS molecule 
remains translocated, the plasma membrane is degraded and permealised allowing 
7-AAD to enter the cell and bind to DNA in the nucleus. Cells staining positive for 7-
AAD only, were undergoing necrosis. In addition camptothecin (Sigma, USA), a 
strong apoptosis inducer, was used to induce apoptosis (positive control) for 
optimization of flow cytometry (Hsiang et al., 1985; Wall et al., 1966).   
In a 6 well plate 250 000 cells were seeded and incubated for 18 hours at 37 ºC. 
Once cells had reached 70-80% confluence they were stimulated with 5µM 
camptothecin for 4 hours. Thereafter cells were washed with warm 1XPBS and 
trypsinized with 2mM EDTA/1XPBS for 1 minute. Cells were washed twice with 
1XPBS and centrifuged at 150 X g for 5 min according to manufacturer’s instructions 
(FITC Annexin V, BD Pharmingen).  Viable cells were counted prior to antibody 
staining. A total of 1X106 cells were resuspended 1ml 1× Binding Buffer, 100µl of the 
solution (1X105 cells) was transferred to a 5 ml culture tube and stained with 5µl 
Annexin V FITC and 5µl 7-AAD and incubated for 15 minutes in the dark. Cells were 
washed in 450µl binding buffer solution and centrifuged at 150 X g for 5 minutes to 
remove unbound antibody. Cells were resuspended in 450µl binding buffer solution 
before visualizing apoptosis with flow cytometry.  
 
4.2.6 HIV-1 Tat induced apoptosis and flow cytometry assays 
Transfection of 293T cells with tat mini-genes 
Cells intended for transfection were seeded in 6 well plates at a concentration of 250 
000 cells and incubated at 37ºC supplemented with 5% CO2 in NUAIRETM US 
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Autoflow CO2 Water-Jacketed Incubator (Nuaire, USA) overnight. Once cells had 
reached approximately 70% confluence old tissue culture medium was replaced with 
fresh medium.  A transfection complex consisting of 100µl DMEM, 3µl transfection 
media and 1µg/µl DNA was prepared and allowed to incubate for 15 minutes before 
being added to 293T cells in a drop-wise manner. Cells were incubated at 37ºC 
supplemented with 5% CO2 in NUAIRETM US Autoflow CO2 Water-Jacketed 
Incubator (Nuaire, USA) for 18 hours. 
 
Antibody staining of transfected 293T Cells  
Cell populations were trypsinized with 2mM EDTA/1XPBS for 1 minute. Cells were 
centrifuged at 150 X g for 5 minutes and the supernatant discarded. Cells were then 
washed with 1X PBS and centrifuged at 150 X g for 5 minutes and the supernatant 
discarded, the wash step was repeated once more before 1X105 cells were re-
suspended in 450µl binding buffer. Cells were stained with 5µl of Annexin V and 5µl 
7-AAD and incubated in the dark for 15 minutes. Cells were washed as previously 
described and then resuspended in 450µl binding buffer. Samples, negative control 
tubes, consisting of a pSV-β-Galactosidase vector control and transfection media 
only control tubes and one positive control tube containing camptothecin were 
analyzed on a four color FACS Calibur flow cytometer (Becton Dickson, USA). 
Identification and gating of apoptotic cell populations 
Apoptotic and non-apoptotic cells were differentiated from each other with the use of 
flow cytometry using the FACS Calibur (Becton Dickenson (BD) Bioscience, USA) 
and CellQuest Pro (Becton Dickenson (BD) Bioscience, USA). A maximum of 10 000 
– 20 000 cell events were acquired. The cells were gated based of forward scatter 
vs. side scatter (to exclude debris and or cell clumps) and then further divided into 
four cell populations using a quadstat dot-plot comparing the two fluorescent dyes as 
indicated in Figure 4.6. Cell populations consisted of non-apoptotic cells which were 
negative for both antibodies, early apoptotic cells which were negative for 7-AAD and 
positive for Annexin V FITC, late apoptotic cells were positive for both Annexin V 
FITC and 7-AAD while necrotic cells were positive for 7-AAD. Quadrant statistics 
were generated after identifying observed apoptotic cells and used in a camptothecin 
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optimized assay to determine the percentage of cells in each described apoptotic 
stage. Mean percentage values were used to determine the level of apoptosis 
induced by each clone, and were compared and analyzed to determine any 
statistical significance. Statistical analysis was performed in graphpad and a two way 
analysis of variance (ANOVA) for repeated measures was performed to compare 
differences in time points. Samples with a p value ≤ 0.05 were deemed significant. 
Instrument settings and color compensation was performed using stained beads (BD 
Biosciences, USA). Manual compensation, to obtain optimal visualization of cell 
populations, was performed using 293T cells which were either untreated or induced 
into apoptosis with camptothecin. Color compensation was not a concern as the two 
fluorescent markers used to stain cells did not have any spectral overlap. Unstained 
cells were used to ensure that non-specific or auto fluorescent signal detection did 
not occur. These settings were used for subsequent apoptosis assays. 
 
4.3. Results 
4.3.1 Construction of HIV-1 tat genes 
Construction of mini-genes were performed by IDT and sequenced to ensure that the 
tat gene sequence was in frame for proper protein expression. Each sequence was 
cloned into a pIDTSMART vector containing M13 forward and reverse sites, an 
ampicillin resistant gene and a site of origin. The vector was 2434bp in size and 
1.503g/mol. In addition, the vector also contained sites for restriction enzyme Pme1 
and Sgf1 for easy transfer between CMV flexi vectors (Promega, USA). The 
sequences for each constructed tat gene are indicated in Figure 4.2 below: 
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>Flexi_Tat206_WT-CS_minigene  
GCCGGCGATCGCCATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACTCC
TTGTAATAAGTGCTATTGTAAACACTGTAGCTATCATTGTCTAGTTTGCTTTCAGACAAAAGGCTTAGGCATTTC
CTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCAAGCAGTGAGGATCATCAAAATCTTATATCAAA
GCAGCCCTTACCCCAAACCCGAGGGGACCCGACAGGCTCGGAAGAATCGAAGAAGAAGGTGGAGAGCAAGACAGA
GACAGATCCATTCGATGTTTAAACACGG 
 
>Flexi_Tat206_CC_minigene  
GCCGGCGATCGCCATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACTCC
TTGTAATAAGTGCTATTGTAAACACTGTTGCTATCATTGTCTAGTTTGCTTTCAGACAAAAGGCTTAGGCATTTC
CTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCAAGCAGTGAGGATCATCAAAATCTTATATCAAA
GCAGCCCTTACCCCAAACCCGAGGGGACCCGACAGGCTCGGAAGAATCGAAGAAGAAGGTGGAGAGCAAGACAGA
GACAGATCCATTCGATGTTTAAACACGG 
 
>Flexi_Tat206_CA_minigene  
GCCGGCGATCGCCATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACTCC
TTGTAATAAGTGCTATTGTAAACACTGTGCCTATCATTGTCTAGTTTGCTTTCAGACAAAAGGCTTAGGCATTTC
CTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCAAGCAGTGAGGATCATCAAAATCTTATATCAAA
GCAGCCCTTACCCCAAACCCGAGGGGACCCGACAGGCTCGGAAGAATCGAAGAAGAAGGTGGAGAGCAAGACAGA
GACAGATCCATTCGATGTTTAAACACGG 
 
>Flexi_Tat206_OPT_minigene  
GCCGGCGATCGCCATGGAGCCCGTGGACCCCAACCTGGAGCCCTGGAACCACCCCGGCAGCCAGCCCAAGACCCC
CTGCAACAAGTGCTACTGCAAGCACTGCAGCTACCACTGCCTGGTGTGCTTCCAGACCAAGGGCCTGGGCATCAG
CTACGGCCGCAAGAAGCGCCGCCAGCGCCGCAGCGCCCCCCCCAGCAGCGAGGACCACCAGAACCTGATCAGCAA
GCAGCCCCTGCCCCAGACCCGCGGCGACCCCACCGGCAGCGAGGAGAGCAAGAAGAAGGTGGAGAGCAAGACCGA
GACCGACCCCTTCGACgttTAAacacgg 
 
Figure 4.2: Nucleotide Sequence of constructed Mini-genes. Four tat genes were 
constructed each with a different mutation in the 30/31 positions of tat. The presence of start 
and stop codons, restriction enzymes sites and the 30/31 positions are indicated  
 
4.3.2 Screening of tat genes in donor vector 
Tat gene transfer between donor (pF4A CMVd1 Flexi® Vector) and acceptor vectors 
(pFN22K CMVd1 Flexi®Vectors) was verified by the amplification of the tat gene. 
Four colonies per mini-gene were screened for the presence of tat inserts. Positive 
products were visualized with gel electrophoresis and ethidium bromide. These 
results indicated that the cloning of the tat mini-genes was successfully completed in 
both the donor and acceptor vector.    
4.3.3 Detection of possible mycoplasma contamination 
Mycoplasma infection has been shown to alter the normal functioning of cell lines 
such as growth, viability, metabolism and biological properties and can therefore 
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become a serious problem once cells have been contaminated. It is especially 
difficult to identify as it cannot be detected with normal light microscopy. It is 
therefore important to screen cell lines for mycoplasma infection on a regular basis. 
Cell cultures were screened with RIDASCREEN® Mycoplasma IFA, an assay which 
utilizes monoclonal antibodies for the detection of a broad spectrum of Mycoplasma 
species which include Acholeplasma laidlawii, Mycoplasma hyorhinis, M. arginini, M. 
orale, M. fermentans and M. salivarium, which account for more than 96% of cell 
culture infections (Blazek et al., 1990; Kamla et al., 1992). Initial screening of cell 
cultures with RIDASCREEN® Mycoplasma IFA appeared suspicious however, it was 
not clear if the culture was indeed infected with mycoplasma or perhaps another 
microorganism. The possible contamination of the cell culture resulted in the entire 
cell line to be discarded as well as any media being used at that time. All surfaces 
used for the culturing and incubation of cells were disinfected with Biocide, Alcohol 
and Contrad, fresh media and a new vial of cells was also cultured to ensure the cell 
line was free of any contamination. The new cell culture was again screened for 
infection with RIDASCREEN® Mycoplasma IFA as indicated in Figure 4.3. The 
immunofluorescence assay did not show any signs of contamination and could 
therefore now be used for transfection and other experiments. No other incidents of 
contamination occurred with the growth of new 293T cells and the use of new growth 
media. 
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Figure 4.3: Immunofluorescence staining for the presence of mycoplasma infection. (A) 
Negative mycoplasma control, (B) positive mycoplasma control, cells stained with green inclusions 
indicates the presence of mycoplasmas, (C) 293T cell cultures intended for transfection, were 
screened for the presence of mycoplasmas with immunofluorescence staining. No contamination by 
mycoplasmas was detected.  
 
4.3.4 Optimization of apoptosis assay 
Camptothecin, a cytotoxic quinolone alkaloid, is capable of inhibiting DNA enzyme 
topoisomerase I (topo I) and is commonly used in apoptotic assays. Camptothecin 
was used here to optimize flow cytometry detection using two concentrations (2.5µM 
and 5µM) to induce apoptosis in the 293T cells at three time periods, 4hours, 6hours 
and 24hours. Optimum apoptosis conditions was observed with 5µM camptothecin 
incubated for 4 hours as longer incubation periods showed high levels of necrosis or 
complete decimation of 293T cells. Figure 4.4 illustrates the forward vs. side scatter 
dot plot used to exclude debris and gate on live and apoptotic cells.  
 
 
 
 
 
 
C 
A                                  B                                 C 
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Figure 4.4: Gating strategy to identify non-apoptotic and apoptotic cell populations. (A) Cell of 
interest are isolated using a gate on a forward and side scatter plot (B) Untreated cells are found in 
the lower left quadrant of a 7-AAD vs. Annexin V FITC scatter plot (C) while early and late apoptotic 
cells could be identified in the lower right and upper right quadrants respectively.    
 
4.3.5 Apoptosis induction of 293T cells by tat mini-genes 
Apoptosis analysis was performed on the flow cytometer using CellQuest Pro (BD, 
USA) software. A scatter plot was created and cells were gated to exclude doublets, 
a second plot was generated from the gated cells as indicated in Figure 4.5. Cells 
that were positive for the Annexin V marker were identified as early apoptotic cells, 
whereas cells staining positive for both 7-AAD and the Annexin V markers were 
labeled as late apoptotic cells. Cells which were negative for both fluorescent dyes 
were considered as non-apoptotic while cells positive for 7-AAD only were 
considered necrotic.  
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Figure 4.5 Percentage of apoptotic 293T cells by Annexin V and 7-AAD. Scatter plots represents 
apoptotic results for (A) transfection media control, (B) vector only control, (C) C30C31 clone, (D) 
C30S31 clone, (E) Optimized clone and (F) C30A31 clone. Different cell populations could be 
identified in each quadrant of the scatter plots: Non-apoptotic cells in the lower left quadrant, early 
apoptotic cells in the lower right quadrant, late apoptotic cells in the upper right quadrant and necrotic 
cells in the upper left quadrant. Percentages of cells undergoing apoptosis have been included in 
quadrants of interest.  
 
Assays were performed in triplicate to determine an apoptotic trend amongst the Tat 
clones however the level of apoptosis from one experiment to the other was not 
reproducible for all cell populations. Differences in cell viability occurred despite cell 
cultures and Tat clones being treated the same and could possibly have influenced 
apoptosis assays. In addition varying degrees of necrosis was also detected as 
evident by scatter plots (A-F) in Figure 4.5. Cell viability for each clone and control 
has been shown in Table 4.1 for each apoptosis assay. 
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Table 4.1: Detected cell viability in control and tat clones  
                                       Cell Viability (%) 
Transfection 
media 
Vector Optimized 
clone 
C30C31 
clone 
C30S31 
clone 
C30A31 
clone 
Experiment 1 57 53 78 75 56 87 
Experiment 2 63 55.36 68.75 72.07 76.47 68 
Experiment 3 50 66.67 54.55 60.47 71.43 56 
Mean value 56.67 58.34 67.1 69.18 67.97 70.33 
Standard 
deviation 
6.51 7.31 11.81 7.68 10.67 15.63 
 
The levels of apoptosis were determined as a percentage of apoptotic cells in the 
entire cell population. The total mean percentages of apoptosis induced by Tat 
clones and controls have been indicated below in Table 4.2. Overall, all Tat clones 
displayed total mean apoptotic levels greater than 20% except the C30S31 clone 
which was identified with the lowest level of total mean apoptotic events at 17%. The 
optimized Tat clone was identified as having the greatest level of apoptotic events 
with a total mean apoptotic percentage of 37.45%. 
 
Table 4.2 Total mean percentage of apoptosis induced by Tat clones and controls 
Tat clones and 
Controls 
Total mean percentage of 
apoptosis detected (%) Clade specific apoptosis (%) 
Transfection media (neg) 16.00 (± 9.65 SD) - 
Vector (neg) 22.34 (± 23.22 SD) - 
CA clone 26.34 (± 13.49 SD ) 4 
CS clone 17.00 (± 17.69 SD) - 
CC clone 28.36 (± 10.83 SD) 6.02 
Optimized clone 37.45 (± 19.08 SD) 15.11 
 
Analysis of early and late apoptosis data identified a trend amongst Tat clones with 
most cells being characterized as being late apoptotic as illustrated in figure 4.6. The 
optimized Tat clone was the only exception to this trend and displayed the highest 
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level of early apoptotic events with a mean percentage of 20.34%. The C30S31 Tat 
clone was identified with the lowest mean percentage for both early (5.87%) and late 
(11.13%) apoptotic events while the C30C31 was identified as having the highest 
mean percentage for late (18.96%) apoptotic events. Surprisingly the Tat clone with 
the C30A31 mutation, displayed a similar pattern of apoptosis as the Tat clone 
containing the C30C31 mutation. The Tat clone with the C30A31 mutation had a 
mean percentage of 7.92% for early apoptosis and 18.42% for late apoptosis.  
 
    
Figure 4.6 Percentage of cells undergoing early and late apoptosis. The figure illustrates, on the 
Y-axis, the percentage of cells undergoing early or late apoptosis with controls and samples being 
indicated on the X-axis. The error bars indicate the standard deviations in the reported measurements 
done in triplicate. The transfection media and empty vector were used as negative controls. Four 
samples were analyzed consisting of an optimized clone, C30C31 clone, C30S31 clone and a 
C30A31 clone.  
 
A t-test for dependant samples and a 2-way ANOVA were performed to determine 
the statistical significance of the level of apoptosis being induced by each Tat clone 
as well as the levels of early and late apoptotic events. However, no statistical 
significance could be observed for both tests. The 2-way ANOVA analysis between 
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early and late apoptosis generated a p-value of 0.83, while the p-values for the 
interaction between Tat clones were all p>0.05.  
 
4.4. Discussion 
Transfection and Apoptosis induction of 293T cells by tat mini-genes 
HIV-1 Tat has been associated with the pathogenesis of neuro-AIDS and has been 
identified as a highly toxic protein capable of inducing apoptosis in astrocyte and 
microglial cell cultures (Mishra et al., 2010). Tat is most abundant in its 101 amino 
acids form, which is characteristic of subtype C infections.  However , truncated 
forms composed of 72 and 86 amino acids have been more commonly used in HIV-1 
Tat studies, especially Tat HXB2 (86), a laboratory-passaged subtype B strain 
(Campbell et al., 2005; Li et al., 2012). Here, we investigate the apoptotic effects of 
full length Tat proteins, containing subtype B (C30C31) and subtype C (C30S31, 
C30A31) mutations expressed in 293T cell culture by CMV mammalian expression 
vectors. 
Analysis of cells undergoing apoptosis were divided into one of three categories, 
early apoptotic events: cells staining positive for Annexin V, late apoptotic events: 
cells dual positive for Annexin V and 7-AAD and total apoptotic events: the sum of 
both early and late apoptotic events. Overall, the optimized clone generated the 
highest level of total apoptosis of 37.45%. This was anticipated, as this clone had 
been codon optimized for protein expression in mammalian cells. C30C31, C30A31, 
and C30S31 showed total mean apoptosis levels of 28.36%, 26.34% and 17.00% 
respectively. The low levels of apoptosis observed in C30S31 correlated to previous 
reports from another study by Mishra et al (2010) which showed that the C31S 
mutation resulted in lower levels of apoptosis in vitro. However it was not expected 
that the level of apoptosis observed with the C30S31 mutation would be lower than 
the vector only control which had a mean apoptosis level of 22.34%. Yet, C30S31 
apoptosis induction was still higher than the transfection media control (16%), though 
not by much. This would suggest that the vector alone was capable of inducing 
apoptosis. However, this observation could have been confounded by the variability 
in cell viability observed during the experiments. Cell viability was reasonably high 
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and ranged between 67.1% and 70.33% for Tat clones while cell viability for 
transfection media and vector only controls was 56.67% and 58.34% respectively. 
Assessing the apoptotic capabilities of Tat clones has therefore been more 
challenging as pseudo apoptosis levels observed in controls could have been 
associated with cell viability. To overcome this problem future study should make 
use of a transfection marker, such as Halo tag, to isolate cells which have been 
transfected and are undergoing apoptosis.  
Nevertheless, the two clones C30C31 and C30A31 were still able to induce 
apoptosis above both control levels. Furthermore, the novel mutation C30A31 
produced early and late apoptosis levels similar to the apoptotic levels observed with 
the clone with the C30C31 mutation. For the clone with the C30A31 mutation, a 
mean apoptotic level of 7.92% was observed for early apoptosis and 18.42% was 
observed for late apoptosis, while the clone with the C30C31 mutation induced 
apoptotic levels of 9.39% for early apoptosis and 18.96% for late apoptosis. It is 
unclear if these are typical apoptosis levels for C30A31, as this mutation has 
previously not been described in the literature. Nonetheless, the levels of apoptosis 
induced by clones with the C30C31 mutations were comparable to those reported in 
a study conducted by Campbell et al. (2005), which compared apoptosis induction of 
full length Tat to that of the HXB2(86) form. 
4.5. Conclusion 
In summary, the findings of these experiments showed that Tat clones were capable 
of inducing apoptosis. The apoptosis induced by the Tat clone containing the 
C30C31 mutation was however more robust than that of the Tat clone with the 
C30S31 mutation.  Therefore demonstrating that the naturally occurring subtype C 
mutation should be regarded as defective. However the C30A31 mutation has also 
demonstrated that subtype C is capable of apoptotic potency similar to that found in 
subtype B and highlights the importance of protein functionality of different HIV-1 
subtypes.  
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CHAPTER FIVE 
Overall Discussion and Conclusion 
5.1 Discussion  
In recent years the prevalence of HIV-1 in South Africa has resulted in a gradual 
plateau; however growing evidence has shown that many infected individuals also 
develop many neurological deficits which include encephalitis, cognitive slowing and 
HAND.  
There is currently little information available regarding HAND cases especially in 
South Africa as many genetic and functional studies conducted on HAND patients 
have been focused on either subtype B or Indian subtype C strains. Studies have 
identified a multitude of pathways as well as genetic and cellular factors which 
contribute to the progression of HAND which include HIV-1 intrinsic and extrinsic 
apoptotic pathways, proteins such as HIV-1 Tat and chemokine’s and cytokines such 
as Interferon α and Fas ligand. Furthermore factors such as subtype specificity have 
also been implicated as a possible contributing factor of HAND pathogenesis. This 
idea has been strengthened by the fact that most HAND cases occurred in 
individuals infected with subtype B strains than subtype C strains. However these 
results may be biased as subtype C is most prevalent in developing countries found 
in Africa and Asia where HAND prevalence may be poorly documented. 
Nonetheless, it cannot be denied that subtype B and subtype C HIV strains are 
genetically distinct. This is most evident in subtype C conserved V3 loop, triplicate 
NF-B enhancers in the long terminal repeat region and mutations present in the Tat 
motif (Travers et al., 2004). A number of mutations have been identified and have 
shown a preference towards certain subtypes. The C30S31 mutation shows a 
greater propensity for subtype C HIV-1 strains while subtype B appears to be 
dominated by the C30C31 mutation. It has been suggested that the amino acid 
change, in the 31 position of the Tat motif is what makes subtype B so much more 
pathogenic that it’s subtype C counterpart and aids in the progression of HAND by 
inducing apoptosis in neurons.  
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This study focused on infected patients in the Cape Town area and consisted of a 
small cohort of 64 patients. Previous studies conducted in South Africa has primarily 
focused on the clinical aspects of HAND such as the impact of HIV-1 on 
neurocognitive functioning and the effect of HAART in the CNS (Joska et al., 2012; 
Moshani 2011). This is the first South African study which attempts to investigate the 
viral epidemiology of a HAND patient cohort, identify signature pattern residues 
which are divergent between subtype C and subtype B sequences and analyze Tat 
motif mutations on a functional level.  
Preliminary genetic subtyping of the HAND cohort identified 6 possible recombinant 
sequences with a large majority of them being identified as subtype C, which was 
expected as subtype C is one of the most prevalent subtypes in Cape Town 
(Engelbrecht et al., 2011). However, upon further inspection it was determined that a 
total of 15 sequences were in fact recombinant forms with either intra-subtypes or 
inter-subtypes being identified. The identification of inter-subtype recombinants not 
only indicates the introduction of new viral subtypes for the Cape Town HIV-1 
population but also suggests a shift in the epidemiological paradigm. Furthermore, 
the identification of intra-subtype C recombinants suggests that the level of 
recombination in Cape Town may be higher than previously thought, as recombinant 
subtype C strains may mistakenly be identified as pure subtype C strains.  
In addition 6 sequences were identified as having resistance mutations, which 
translates as 12.7% of the screened pol sequences. Given the fact that this is a 
small cohort it may be an inaccurate depiction of the actual level of resistance 
currently experienced in the study population. However, as resistance testing is only 
initiated after treatment failure, this finding may have implications for anti-retroviral 
treatment plans, especially since this is a treatment naïve cohort. This also suggests 
that treatment naïve patients with pre-existing resistance may have a greater chance 
of experiencing first line therapy failure.  
Signature pattern analysis identified areas of relative conservation within the six 
domains of Tat between the three sequence subsets however this was outweighed 
by the level of variability observed in the cysteine rich, glutamine-rich and C-terminal 
domains. As expected, cohort sequences showed great similarity to other subtype C 
sequences from India and South Africa, although in some instances this similarity, 
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though to a lesser degree, was also shared between cohort sequences and subtype 
B sequences. In addition, while tat motif mutations in subtype B sequences were 
only C30C31, subtype C sequences from the cohort, South Africa and India had a 
mixture of both C30C31 and C30S31 mutations.  
5.2 Strengths and Limitations of study for possible future work 
This study has highlighted the importance of continued HIV-1 surveillance for the 
detection and proper identification of new circulating HIV-1 strains and the need for 
resistance screening of treatment naïve patients. However, a number of aspects in 
this study were found to be limiting and could be improved for possible future 
studies. 
Firstly the cohort size was too small to give a clear indication of the level of diversity 
in the South African HAND study population. This was further compounded by the 
fact that cohort patients were only sampled from 3 clinics in Cape Town. The study 
however provided a foundation for further analyses which could possibly compare 
the diversity of HAND patients from various provinces. 
Secondly, the lack of available data regarding Tat motif mutations in South Africa 
meant that any comparisons of the novel mutation (C30A31) identified in the cohort 
was restricted to subtype B and Indian subtype C sequences. The identification of a 
novel mutation has prompted further analyses and asks some important questions, 
what is the prevalence of the C30A31 mutation, is the C30A31 mutation genetically 
significant for subtype C, is there a possibility of other novel mutations circulating 
amongst the HIV infected and if so are they unique to the South African HAND 
population.  
Thirdly, 293T cells, an adherent kidney cell line, were used for the functional 
analyses of HIV-1 Tat since it is easily cultured and transfected. However, HIV-1 Tat 
is neurotoxic in nature and it would therefore be useful to investigate the apoptotic 
effects of Tat in cell lines derived from neurons, monocytes and astrocytes as the 
latter are especially prone to infection by HIV-1 crossing the blood brain barrier into 
the CNS.  
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Finally, statistical analysis showed no significance in the level of apoptosis being 
induced by each clone. A possible explanation for this outcome could be that only 
three repeats were performed for this experiment. In addition the level of variability 
between each experiment with regard to cell passage number and cell viability may 
have influenced the overall level of apoptosis being detected. In order to overcome 
this problem and to clearly differentiate between typical cell apoptosis and Tat 
induced apoptosis, transfected cells could in future be labeled with a marker such as 
Halotag. 
5.3 Conclusions 
This project gave some important insight into HIV-1 tat in a HAND study cohort in 
South Africa; however larger studies are warranted to determine whether or not the 
identified trends are significant. 
A high level of variability was detected with a total of 15 recombinants being 
identified. Possible recombinants consisted of 6 inter subtype recombinants and 9 
intra-subtype C recombinants being identified.  In addition 12.76% of pol sequences 
were identified with resistance mutations with half of these mutations manifesting in 
recombinants. Furthermore, signature pattern analysis identified variability between 
subtype C and subtype B tat sequences with the C30S31 dicysteine motif being 
relatively conserved in both Indian and South African subtype C sequences. 
However it should be noted that a number of sequences in the cohort and South 
African cohort also exhibited the wild type subtype B C30C31 mutation. In addition a 
novel mutation was identified in one sequence. This is the first identification of this 
mutation and may have implications for HAND as this mutation induced a similar 
level of apoptosis displayed by the C30C31 mutation.  
However this project was not without its flaws, therefore the limitations previously 
discussed warrant further investigation before conclusions can be drawn about each 
Tat mutation and their ability to actively induce apoptosis in cell culture.   
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Appendix A 
Table 1: Patient demographics 
Sample # Gender Age Clinic CD4 
count 
cells/µl 
Clinical 
JO152 Female 30 WDH 185 MND 
JO161 Female 32 NHC 307 MND 
JO162 Female 26 NHC 361 MND 
JO166 Female 33 UBN 75 Dementia 
JO167 Female 35 NHC 409 MND 
JO168 Female 30 UBN 335 MND 
JO172 Female 29 NHC 929 Dementia 
JO173 Female 34 NHC 398 MND 
JO176 Female 26 NHC 282 Normal 
JO179 Female 25 UBN 143 MND 
JO180 Female 32 WDH 184 Normal 
JO183 Female 33 UBN 201 MND 
JO185 Female 25 NHC 318 MND 
JO186 Female 31 UBN 152 ANI 
JO189 Male 32 UBN 194 MND 
JO190 Female 30 UBN 217 MND 
JO191 Male 29 UBN 112 ANI 
JO192 Female 35 NHC 172 MND 
JO193 Male 26 UBN 172 MND 
JO195 Male 35 UBN 146 ANI 
JO196 Male 20 UBN 116 NA 
JO198 Female 26 UBN 140 Dementia 
JO200 Male 34 WDH NA Normal 
JO201 Male 30 WDH NA MND 
JO202 Female 28 UBN 107 Dementia 
JO203 Female 29 UBN 180 Normal 
JO204 Female 34 UBN 199 Normal 
JO206 Female 30 NHC 198 Dementia 
JO207 Female 35 NHC 192 MND 
JO209 Female 33 WDH 118 MND 
JO210 Female 33 UBN 120 Normal 
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JO213 Male 27 UBN 164 Normal 
JO214 Female 28 WDH 165 MND 
JO215 Female 32 WDH 192 Normal 
JO216 Male 35 WDH 107 Dementia 
JO218 Female 25 UBN 191 NA 
JO219 Female 36 UBN 185 NA 
JO220 Male 26 UBN 196 MND 
JO223 Female 31 WDH 190 Normal 
JO224 Female 35 WDH 182 Dementia 
JO225 Female 34 UBN 196 Dementia 
JO229 Female 29 UBN 180 Dementia 
JO230 Female 32 UBN 100 Normal 
JO231 Female 27 UBN 190 Normal 
JO232 Male 32 UBN 135 Normal 
JO233 Female 30 UBN 107 ANI 
JO234 Male 30 Unknown 81 Normal 
JO235 Female 30 WDH NA Normal 
JO236 Female 32 UBN 139 Normal 
JO237 Female 31 UBN 184 MND 
JO238 Male 32 UBN 71 MND 
JO239 Female 32 UBN 191 MND 
JO240 Female 31 UBN 177 Dementia 
JO241 Male 31 UBN 52 MND 
JO244 Female 28 UBN 66 MND 
JO247 Female 33 NHC 184 MND 
JO248 Male 25 NHC 118 Normal 
JO252 Female 25 WDH 186 Dementia 
JO254 Female 27 UBN 182 MND 
JO258 Male 25 UBN 168 Normal 
JO259 Male 21 NHC NA NA 
JO288 Female Unknown UBN 140 NA 
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